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ABSTRACT OF DISSERTATION 
 
 
 
 
USING PRESCRIPTION DRUG MONITORING DATA 
TO INFORM POPULATION LEVEL ANALYSIS 
OF OPIOID ANALGESIC UTILIZATION 
 
Increased opioid analgesic (OA) prescribing has been associated with increased risk 
of prescription opioid diversion, misuse, and abuse. States established prescription drug 
monitoring programs (PDMPs) to collect and analyze electronic records for dispensed 
controlled substances to reduce prescription drug abuse and diversion. PDMP data can be 
used by prescribers for tracking patient’s history of controlled substance prescribing to 
inform clinical decisions.   
The studies in this dissertation are focused on the less utilized potential of the 
PDMP data to enhance public health surveillance to monitor OA prescribing and co-
prescribing and association with opioid overdose mortality and morbidity. Longitudinal 
analysis of OA prescribing and evaluation of the effect of recent policies and opioid 
prescribing guidelines require consensus measures for OA utilization and computational 
tools for uniform operationalization by researchers and agencies. Statistical macros and 
computational tools for OA utilization measures were developed and tested with Kentucky 
PDMP data. A set of covariate measures using mortality and morbidity surveillance data 
were also developed as proxy measures for prevalence of painful conditions justifying OA 
utilization, and availability of heroin and medication treatment for opioid use disorder. A 
series of epidemiological studies used the developed OA measures as outcomes, and 
adjusted for time-varying socio-demographic and health care utilization covariates in 
population-averaged statistical models to assess longitudinal trend and pattern changes in 
OA utilization in Kentucky in recent years. The first study, “Trends and Patterns of OA 
Prescribing: Regional and Rural-Urban Variations in Kentucky from 2012 to 2015,” shows 
significant downward trends in rates of residents with OA prescriptions. Despite the 
significant decline over time, and after accounting for prevalence of injuries and cancer, 
the rate of dispensed OA prescriptions among residents in Kentucky Appalachian counties 
remained significantly higher than the rest of the state. The second study, “Population-
Level Measures for High-Risk OA Prescribing: Longitudinal Trends and Relationships 
with Pain-Associated Conditions,” shows significant reduction in high-risk OA prescribing 
(e.g., high daily dosage, long-term use, concurrent prescriptions for OA and 
 
benzodiazepines) from 2012 to 2016, significantly positive associations between high-risk 
OA prescribing and cancer mortality rates with no substantial change in the association 
magnitude over time, and declining strengths of positive associations between high-risk 
OA prescribing and acute traumatic injuries or chronic non-cancer pain over the study 
period. The third study, “A Reciprocal Association between Longitudinal Trends of 
Buprenorphine/Naloxone Prescribing and High-Dose OA Prescribing,” indicates a 
significant reciprocal relationship between high-dose OA prescribing and buprenorphine/ 
naloxone prescribing, and a clinically meaningful effect of buprenorphine/naloxone 
prescribing on reducing OA utilization.   
The results from the studies advanced the understanding of the epidemiology of 
opioid use and misuse in Kentucky, and identified actionable risk and protective factors 
that can inform policy, education, and drug overdose prevention interventions. The 
developed operational definition inventory and computational tools could stimulate further 
research in Kentucky and comparative studies in other states.  
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CHAPTER ONE 
Introduction 
Excess opioid analgesics prescribing has been deemed the starting point of the 
over two-decade-long opioid crisis in the United States (US).1-3 Increased opioid 
analgesic prescribing is associated with increased risk of prescription opioid diversion, 
misuse, and abuse, transition to illicit drug use, and adverse consequences such as 
nonfatal and fatal overdoses.4-7 A dramatic rise in opioid analgesic prescriptions has been 
observed coinciding with an acceleration in the misuse of prescription opioid analgesics,8 
and an escalation of drug overdose mortality in the US since the 1990s.9,10 In 2016, more 
than 10 million Americans (accounting for four percent of the US adult population) 
misused prescription opioid analgesics,8 and more than 42,000 Americans died of opioid-
related overdose (making up 66% of all overdose deaths).11 Although in recent years 
there has been a declining trend in opioid analgesic prescriptions,12 and overdose deaths 
involving heroin, fentanyl and fentanyl analogs have substantially increased,13 
prescription opioid analgesics remain a significant contributor to overdose deaths and 
initiation of heroin use.14,15  
In order to reduce prescription drug abuse and diversion, states established 
prescription drug monitoring programs (PDMP) to collect and analyze electronic records 
for prescribed and dispensed controlled substances. While the primary role of the early 
PDMPs was to support drug law enforcement investigations, the current role of the 
PDMPs has been extended with a particular focus on enhancing patient care and 
informing drug abuse prevention and treatment programs.16 To date, all states (except 
Missouri) have enacted PDMP legislation and implemented state-based PDMPs.17,18 
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Since the first PDMP, New York State’s in 1918, PDMPs have operated with 
considerable diversity across states and continuously evolving features over time.16,19,20 
Previous PDMP research showed that some PDMP implementation features (e.g. 
monitoring more schedules, providing law enforcement and medicolegal death 
investigators with access to PDMP data, requiring more frequent data reporting, allowing 
unsolicited reporting, requiring prescriber registration with the PDMP, or requiring 
prescriber query of PDMP data prior to prescribing in certain circumstances) are 
associated with reduction or slower rate of increase in state opioid overdose mortality and 
morbidity over time.21-23 
Due to the heterogeneity of PDMPs and the transition from prescription opioids to 
heroin and illicitly produced fentanyl as leading causes for overdose mortality, it is not 
easy to show direct effects of PDMPs on reducing drug overdose deaths.19,24-27 However, 
it is incontrovertible that PDMPs have been continuing to be an effective and important 
tool for prescription drug abuse and diversion prevention.16,19,28-30 Prescribers and 
dispensers can access the PDMP data to track patient’s history of controlled substance 
use to identify patient’s behaviors of misuse and abuse, and patient’s risk of drug 
overdose before writing controlled substance prescriptions. Drug courts, medical 
examiners and coroners, and drug abuse counselors are also allowed to access the data in 
several states.16 
PDMP data can be used by researchers, and public health practitioners to inform 
policy decision making and intervention implementation and evaluation at population 
level.28,30-35  Multiple processing metrics, outcome indicators, and patient behavior or 
prescriber practice measures based on PDMP data have been created by states. Utilization 
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of PDMP measures has varied from state to state. Different measure definitions, scales, 
and thresholds have been adopted in different states. Process and utilization metrics 
commonly reported across states include number of PDMP queries and number of 
registered controlled substance prescribers/pharmacists. Common outcome indicators 
include number of prescriptions, number of persons with any opioid prescription, average 
number of prescription days’ supply, total morphine milligram equivalents dispensed, 
type and volume of dispensed substances, average morphine milligram equivalent dose 
dispensed at prescription or person levels, number of concurrent opioid and sedative 
prescriptions, and number of chronic opioid prescriptions. There are commonly utilized 
measures for identifying potential “doctor shopping” or “pharmacy shopping”, or for 
prescribers with potentially high-risk prescribing patterns. Details regarding tracked 
PDMP-based measures and metrics, obtained from the states’ PDMP websites, are 
presented by state in Table 1.1 – Appendix.18 
PDMP data are a valuable resource to measure prescribing trends and practices, 
drug-seeking behaviors, and outcome indicators for monitoring, surveillance, evaluation, 
and other epidemiological studies, but have been underutilized.28,34,36,37 The studies in 
this dissertation are focused on the potential use of PDMP data to enhance public health 
surveillance to monitor opioid analgesic prescribing and co-prescribing and association 
with opioid overdose mortality, morbidity, and other relevant health outcomes. 
Longitudinal analysis of opioid analgesic prescribing and evaluation of the effect of 
recent policies and opioid prescribing guidelines require consensus measures for opioid 
analgesic utilization and computational tools for uniform operationalization by 
researchers and agencies. Statistical macros and computational tools for opioid analgesic 
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utilization measures were developed and tested with Kentucky PDMP data. A set of 
covariate measures using mortality and morbidity surveillance data were also developed 
as proxy measures for prevalence of painful conditions justifying opioid analgesic 
utilization, and availability of heroin and medication treatment for opioid use disorder. A 
series of epidemiological studies used the developed opioid analgesic measures as 
outcomes, and adjusted for time-varying socio-demographic and health care utilization 
covariates in population-averaged statistical models to assess longitudinal trend and 
pattern changes in opioid analgesic utilization in Kentucky in recent years. The studies 
are described in the next three chapters. 
Chapter Two, “Trends and Patterns of Opioid Analgesic Prescribing: Regional 
and Rural-Urban Variations in Kentucky from 2012 to 2015” addresses important 
questions on longitudinal changes in rates of residents treated with opioid analgesics in 
Kentucky counties, while accounting for time-varying socioeconomic factors, availability 
of primary health care providers, opioid use disorder treatment with 
buprenorphine/naloxone, and rates of major health conditions commonly treated with 
opioid analgesics (e.g., invasive cancer). Of particular interest was the significance of 
potential changes in opioid analgesic prescribing in the Kentucky Appalachian counties, a 
predominantly rural region in economic distress with historically high opioid prescribing. 
The study uses strong statistical methodology and provided sound analytical results. The 
study findings show significant downward trends in rates of residents with opioid 
analgesic prescriptions during the study period. Despite the significant decline over time, 
and after accounting for prevalence of injuries and late-stage cancer, the rate of dispensed 
opioid analgesic prescriptions among residents in Kentucky Appalachian counties 
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remains significantly higher than the rest of the state. The discussion in Chapter Two 
explains the significance of the study results, highlights actionable risk and protective 
factors identified in the study analysis, and provides suggestions for further research and 
action.  
The study in Chapter Three, “Population-Level Measures for High-Risk Opioid 
Analgesic Prescribing: Longitudinal Trends and Relationships with Pain-Associated 
Conditions,” is focused on high-risk opioid analgesic prescribing practices. The study 
objectives were to develop population-level measures for monitoring high-risk opioid 
analgesic prescribing patterns and investigate their longitudinal associations with pain-
related conditions (acute traumatic injuries, chronic non-cancer pain, and invasive 
cancer). The study used Kentucky prescription monitoring data to calculate six 
population-level measures of high-risk opioid analgesic prescribing: high daily morphine 
milligram equivalent dose, long-term opioid analgesic use, long-term use of high daily 
dose, concomitant opioid analgesic and benzodiazepine prescriptions, overlapping opioid 
analgesic prescriptions, and long-acting opioid analgesic prescribed to opioid-naïve 
patients. Marginal models employed generalized estimating equations to evaluate the 
association over time between adjusted rates of high-risk opioid analgesic prescribing and 
rates of pain-associated conditions. Estimated adjusted relative risk ratios are presented 
and their statistical and practical significance in the context of recent prescribing 
guidelines and state policies for opioid analgesic prescribing is discussed. This is the first 
study to provide evidence that the rates of high-risk opioid analgesic prescribing in 
Kentucky, 2012 – 2016,  are positively associated with cancer mortality rates with no 
substantial change in the association magnitude over time, suggesting recent clinical 
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guidance for chronic non-cancer pain have not affected prescribing for cancer pain. 
Given evidence of no advantage of opioid analgesics over non- opioid analgesics for 
chronic non-cancer pain, the decreasing high-risk opioid analgesic prescribing practices 
reported in this study, in the context of increasing chronic non-cancer pain rates in 
Kentucky, is a very encouraging finding and suggests that monitoring high-risk opioid 
analgesic prescribing trends is an important component of data-driven drug overdose 
prevention and enhanced public health surveillance. 
Buprenorphine/naloxone treatment is recommended as a highly effective 
treatment for opioid use disorder. However, very few studies have examined how 
expansion of buprenorphine/naloxone treatment at population level affects opioid 
analgesic prescribing and vice versa. The purpose of the Chapter Four study, “A 
Reciprocal Association between Longitudinal Trends of Buprenorphine/Naloxone 
Prescribing and High-Dose Opioid Analgesic Prescribing,” was to investigate the 
relationships between buprenorphine/naloxone prescribing and high-dose opioid 
analgesic prescribing in Kentucky, 2012-2017. The study employed a cross-lagged 
structural equation analysis to evaluate relationship between rates of residents with 
buprenorphine/naloxone prescriptions and rates of residents with high-dose opioid 
analgesic prescribing (per 1,000 residents with opioid analgesic prescriptions) in relation 
to baseline socioeconomic status, painful conditions and heroin availability. High-dose 
opioid analgesic prescribing at the person-level was defined as at least seven consecutive 
days with a daily cumulative dose of 100 morphine milligram equivalents or more. For 
each quarter-county observation, high-dose opioid analgesic prescribing rate was used to 
predict buprenorphine/naloxone prescribing rate at the next quarter, and simultaneously 
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buprenorphine/naloxone prescribing rate was used to predict high-dose opioid analgesic 
prescribing at the next quarter. The findings suggest a significant reciprocal relationship 
between high-dose opioid analgesic prescribing and buprenorphine/naloxone prescribing, 
and a clinically meaningful effect of buprenorphine/naloxone prescribing on reducing 
opioid analgesic prescribing, highlighting the potential public health benefits of 
buprenorphine/naloxone treatment expansion. 
Chapter Five provides summaries of findings, discusses the limitations of the 
PDMP data, highlights the significance of this dissertation research, and suggests future 
directions for utilizing PDMP data for public health surveillance, research, policy and 
program evaluation. 
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CHAPTER TWO 
Trends and Patterns of Opioid Analgesic Prescribing: Regional and Rural-Urban 
Variations in Kentucky from 2012 to 2015 
Abstract 
Purpose: Increased opioid analgesic prescribing has been associated with increased risk 
of prescription opioid diversion, misuse, and abuse. Regional and rural-urban variations 
in opioid analgesic prescribing trends in Kentucky, from 2012 to 2015, along with 
potential county-level risk and protective factors were examined. 
Methods: This study used prescription drug monitoring data. Marginal models 
employing generalized estimating equations were used to model repeated counts of 
residents with opioid analgesic prescriptions within county-quarter, 2012–2015, with 
offset for resident population, by rural-urban classification exposure, and adjusting for 
time-varying socioeconomic and relevant health status measures.  
Findings: There were significant downward trends in rates of residents receiving 
dispensed opioid analgesic prescriptions, with no regional or rural/urban differences in 
the degree of decline over time. The adjusted models showed the Kentucky Appalachian 
region retained a significantly higher rate of residents with opioid analgesic prescriptions 
per 1,000 residents (30% higher than Central Kentucky and 19% higher than Kentucky 
Delta regions). Residents of non-metropolitan not adjacent-to-metropolitan counties had 
significantly higher adjusted rates of opioid analgesic prescribing (33% higher than 
metropolitan counties and 17% higher compared to non-metropolitan adjacent-to-
metropolitan counties). The rate of opioid analgesic prescribing was significantly 
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positively associated with emergency department visit injury rates and negatively 
associated with buprenorphine/naloxone prescribing rates.   
Conclusions: Information on opioid analgesic prescribing trends and patterns will be 
used by Kentucky stakeholders to inform targeted interventions. Further research is 
needed to evaluate the availability and accessibility of non-opioid pain treatment in rural 
counties and the role of geography and time/distance traveled as risk factors for increased 
opioid analgesic prescribing. 
2.1 Introduction 
Increased opioid analgesic prescribing has been associated with increased risk of 
prescription opioid diversion, misuse, and abuse.4-7 The rates of opioid analgesic 
prescriptions in the United States (US) have risen measurably since the 1990s,38 in 
parallel with a dramatic escalation of opioid overdose deaths.39  Opioid analgesic 
prescribing patterns vary markedly among US geographical regions, with 
disproportionally high opioid prescribing rates in Appalachian, southern, and some 
western states.38,40  Although annual rates of opioid analgesic prescriptions per 100 
persons declined 13.1% nationwide from 81.2 in 2012 to 70.6 in 2015, this decrease was 
observed in only 46.5% of counties rather than in all counties, with large declines in 
some areas and not in others.41  
Multiple factors might contribute to the observed differences in opioid prescribing 
across the US.38,40 One possible explanation is that opioid prescribing is higher in areas 
where access to alternative, non-opioid treatments for chronic non-cancer pain is limited, 
and this may be especially true for rural areas.42-44 Furthermore, rural areas in West 
Virginia, eastern Kentucky, southwestern Virginia, Maine, and Alabama were among the 
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first geographical areas to be targeted by Purdue Pharma in the 1990s for promotion and 
marketing of OxyContin®,45 a leading opioid analgesic of abuse in the US.46 The 
geographical areas first affected by high OxyContin® prescribing also experienced 
increased abuse, diversion, and addiction.45 In addition, increased prescription opioid 
misuse in rural areas has been associated with increased social and family stressors, 
unemployment, and health disparities.42-44 
Kentucky is located in the Southeast region of the US with 71% of its counties 
classified as rural.47 In 2012, Kentucky had the fourth highest prescribing rate of opioid 
pain relievers (excluding buprenorphine products) with 128 prescriptions dispensed per 
100 residents,38 and it had the second highest age-adjusted drug overdose mortality rate in 
the US (25/100,000).48  Besides the aggressive marketing of OxyContin® in eastern 
Kentucky (the Kentucky Appalachian region), the opioid epidemic in Kentucky may be 
attributed to a diversity of factors including: high prevalence of cancer and injury, 
inadequate access to health care services and substance use disorder treatment, and 
cultural and environmental stressors.49-51 In 2012, in response to the opioid crisis, 
Kentucky enacted comprehensive legislation in an attempt to reduce the abuse and 
diversion of prescription opioid analgesics (Kentucky House Bill 1, 2012 Special 
Session)52; subsequent licensure board regulations in 2013 (201 KAR 8:540, 9:260, 
20:057) codified clinical guidelines to controlled substance prescribers by providing 
guidance regarding the frequency and usage of the state’s Prescription Drug Monitoring 
Program (PDMP), urine drug screenings, and patient follow-up protocols.53-55  
This study investigated the trend in opioid analgesic (excluding buprenorphine) 
prescribing in Kentucky from 2012 to 2015, and identified rural-urban as well as 
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geographic region differences in prescribing trends. A decline in the opioid prescribing 
rate, especially in Kentucky counties with historically high prescribing rates was 
hypothesized. Specifically, the research questions were: 
(1) Have the rates of residents with opioid prescriptions significantly changed over 
time?  
(2) Did changes in opioid prescribing over this 4-year period in Kentucky vary by rural-
urban county residency classification, after adjusting for socioeconomic factors, 
availability of primary health care providers, opioid use disorder treatment with 
buprenorphine/naloxone, and rates of major health conditions commonly treated 
with opioid analgesics (e.g., invasive cancer)? 
(3) Were there significant changes in opioid prescribing in the Kentucky Appalachian 
counties, a predominantly rural region in economic distress with historically high 
opioid prescribing?  
(4) What county-level factors were associated with the opioid prescribing rate?  
2.2 Methods 
2.2.1 Data Sources 
Individual-level records of controlled substance prescriptions dispensed in 
Kentucky and reported to the Kentucky All Schedule Prescription Electronic Reporting 
(KASPER) program, Office of Inspector General (OIG), Cabinet for Health and Family 
Services from 2012 to 2015 (45,059,360 total records) were obtained. The Schedule II to 
IV opioid prescriptions, including methadone for pain treatment and excluding 
buprenorphine and buprenorphine/naloxone combinations, were used for the calculations 
of opioid prescribing measures.56 Buprenorphine/naloxone combination transmucosal 
12 
 
(i.e., sublingual or buccal products) prescriptions were used as an indicator for 
medication treatment for opioid use disorders, their Food and Drug Administration 
(FDA)-approved indication.57 The Kentucky Board of Medical Licensure has a regulation 
on buprenorphine prescribing which stipulates that buprenorphine products FDA-
approved for opioid use disorder treatment are not allowed to be prescribed off-label.58 
Methadone dispensed at opioid treatment programs is not reported to the KASPER 
system. 
Multiple data sources were used for the calculation of covariate measures, 
including (1) emergency department (ED) visits data, 2012–2015, from the Kentucky 
Office of Health Data and Analytics (KOHDA); (2) inpatient hospitalizations data, 2012–
2015, KOHDA; (3) invasive cancer incidence data, 2010–2014, from the Kentucky 
Cancer Registry59; (4) socioeconomic status (SES) data, 2012–2015, from the American 
Community Survey (ACS), US Census Bureau60; and (5) primary health care provider 
data, 2012–2015, County Health Rankings and Roadmaps.61  
2.2.2 Measures 
In this ecological study with longitudinal data, measures were calculated at the 
county level and repeated quarterly. In total, there were 1,920 county-quarter 
observations for the 120 Kentucky counties over the study period. 
The outcome of interest was the number of residents with at least one dispensed 
opioid analgesic prescription within each county-quarter. For persons with multiple 
prescriptions within a quarter reported under different resident addresses, the county of 
residence was identified as the most frequently reported county in that quarter. The most 
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recent county reported was selected for a person with tied frequency of resident counties 
reported within a quarter. 
Exposures of interest were: (1) rural/urban status of the county (Rurality) and (2) 
geographical region of Kentucky (Region).  Rurality of a county was measured by the 
Rural-Urban Continuum Codes (RUCC) 2013.62 The codes were categorized based on 
adjacency to a metro area, which may be a proxy for availability of non-opioid pain 
management treatment options, opioid addiction treatment, or access to heroin. A study 
by Brown et al, for example, showed that mean distances to nearest opioid addiction 
treatment centers for pregnant women residing in Kentucky rural/micro and Appalachian 
areas were significantly higher than for those in metropolitan and non-Appalachian 
regions.63 Three groups of rurality/urbanization were defined: (1) metropolitan (metro) 
counties (RUCC 1 to 3); (2) non-metro adjacent to metro (NMAM) counties (RUCC 4, 6, 
8); and (3) non-metro not adjacent to metro (NMNAM) counties (RUCC 5, 7, 9). Three 
regions of Kentucky were studied (Figure 2.1): (1) Delta region that includes 21 far-
western Kentucky counties,64 (2) Appalachian region that includes 54 eastern counties in 
the Appalachian Mountains,65 and (3) Central Kentucky region constituting the remaining 
45 counties in the Bluegrass and Pennyroyal areas. The Delta and Appalachian regions 
are federally designated areas of economic distress.66 
Through review of the literature,40-44,67-69 county-level attributes such as race, 
educational level, poverty, unemployment rate, health insurance coverage, availability of 
prescribers (surgeon, psychiatrist, primary care physician, and dentist density), or the 
prevalence of painful conditions including diabetes and arthritis were found to be 
significantly associated with high opioid analgesic prescribing.  The following county-
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level time-varying covariate measures that may explain differences in opioid analgesic 
prescribing outcome measures among Kentucky counties and regions were considered: 
(1) socioeconomic factors, including percentage of population aged 55 or older,70 
percentage of white residents (excluding multiracial residents), median annual income, 
percentage of population aged 25 or older with a high school diploma, unemployment 
rate; (2) proxy indicators for access to opioid prescribers, namely rate of primary care 
physicians per 1,000 residents, and percentage of noninstitutionalized civilians with 
health insurance coverage; (3) proxy indicators for medical need for analgesic opioids, 
entailing rates of inpatient hospitalizations and ED visits involving non-cancer chronic 
pain (any principal or secondary diagnosis of 338.21, 338.22, 338.28, or 338.29 for ICD-
9-CM-coded data, or any principal or secondary diagnosis of G89.21, G89.22, G89.28, or 
G89.29 for ICD-10-CM-coded data), rate of ED visits due to acute traumatic injuries 
(excluding all poisonings), age-adjusted incidence rates of invasive cancer averaged over 
the two years prior to the year of modeled opioid prescribing, and percentage of 
noninstitutionalized civilians with any disability; (4) a proxy for availability of 
medication treatment for opioid use disorders that is rate of residents with 
buprenorphine/naloxone combination prescriptions per 1,000 residents with any opioid 
analgesic prescription; and (5) a proxy for heroin availability in a county—rate of ED 
visits for treatment of heroin-related overdoses per 1,000 residents. Assessment of 
collinearity between the covariates indicated that there was no significant effect of 
multicollinearity as the Spearman correlation coefficients of the factors were less than 
0.70, and the variance inflation factors were all less than 10. Data sources for the listed 
measures are presented in Table 2.1. 
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2.2.3 Statistical Analysis 
Descriptive Analyses. Quarterly averages for the defined outcome measure were 
compared by geographic region and by rural-urban county classification. The cross-
sectional measures presented in Table 2.2 describe the geographical regions as well as the 
rural-urban classification groups in terms of SES, prevalence of painful conditions, and 
other relevant measures introduced in Section 2.2.2.  
The spatial distribution of the opioid analgesic prescribing county-level outcome 
measures were visualized using ArcGIS 10.3 (ESRI, Redlands, CA) with referent 
geographical data of county boundary polygons of Kentucky, downloaded from the 
Kentucky Geography Network.71 SAS® 9.4 (SAS Institute Inc., Cary, NC) was used for 
all statistical analyses and modeling.  
Longitudinal Trends. Repeated measures log-linear models were used to evaluate trends 
over time and differences among the regions on the number of residents with dispensed 
opioid analgesic prescriptions. As the outcome data were calculated as counts, the 
Poisson regression framework was initially used with adjustment terms for exposed 
population, i.e., an offset by the natural logarithm of the population size. Thus, the 
repeated measures analysis estimated rate ratios among exposed groups, and their 95% 
confidence intervals (CI).  
Due to evidence for over-dispersion in the Poisson model fit, the final regression 
models were conducted as generalized estimating equations (GEE) using the log link 
function and negative binomial distribution (PROC GENMOD, DIST=NEGBIN, 
LINK=LOG, REPEATED SUBJECT, TYPE=AR). Autoregressive assumption for the 
working covariance structure was employed, meaning that intra-subject measurements 
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are correlated but as measurements get farther apart the strength of the correlation 
diminishes.  
To further investigate variations in the opioid analgesic prescribing measure, two 
models were compared: a model with a main exposure variable Region, and a model with 
a main exposure variable Rurality. The unadjusted models included only the main effect 
for Time and main exposure (Region or Rurality, respectively). To determine if opioid 
analgesic prescribing trends changed at different rates over time among the exposed 
groups, a by-time interaction with the main exposure variable was included in each 
adjusted model. The adjusted models controlled for (1) the rate of ED visits for injury, (2) 
the percentage of population aged 55 or older, (3) the percentage of population aged 25 or 
older with a high school diploma, (4) the percentage of noninstitutionalized civilians with 
health insurance, and (5) the rate of residents with buprenorphine/naloxone prescriptions. 
These five covariates were selected from the full models including all 13 covariates 
described in Section 2.2.2 by a backward selection strategy with a significance level of 
five percent. The interaction terms “Time×Region” and “Time×Rurality” were not 
significant and were dropped from the corresponding final adjusted models. The 
estimated quarterly opioid analgesic prescribing rates adjusted for the covariates in the 
final models with their 95% confidence limit bands were plotted by Region and by 
Rurality separately.  
In addition, sensitivity analyses were performed to account for the 
implementation of two main policies during the study period: (1) the licensure board 
regulations providing clinical guidelines for controlled substance prescribing, effective as 
of the third quarter of 2013 (201 KAR 8:540, 9:260, 20:057),53-55 and (2) the Drug 
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Enforcement Administration (DEA) rescheduling of hydrocodone combination products 
as Schedule II controlled substances, effective as of the last quarter of 2014.72 The results 
from the sensitivity analyses demonstrated that the estimated effects for Time and 
Region/Rurality designations did not change in significance and direction. 
2.3 Results 
2.3.1 Descriptive Analyses 
Table 2.2 provides descriptions of the study population characteristics for each of 
the exposure groups (Region or Rurality). On average from 2012 to 2015, the 
Appalachian region counties as well as the NMNAM counties were more likely to have a 
significantly lower percentage of the population with a high school diploma, average 
median income, and percentage of noninstitutionalized civilians with health insurance, 
and significantly higher rates of unemployment, ED visits due to acute injuries, ED visits 
and inpatient hospitalizations involving non-cancer chronic pain, and percentage of 
noninstitutionalized civilians with disability compared to the rest of the corresponding 
exposure groups of counties. The Appalachian region had a significantly higher rate of 
residents with buprenorphine/naloxone combination prescriptions (58 per 1,000 residents 
with opioid prescriptions) than the Delta region (12/1,000; p< .0001) and the Central 
Kentucky region (19/1,000; p< .0001). The Appalachian region also had significantly 
higher age-adjusted incidence rates of invasive cancer in comparison to the Delta and 
Central Kentucky regions. 
During the study period, there were 21,096,420 opioid analgesic prescriptions, 
excluding buprenorphine or buprenorphine/naloxone combinations.  In 2015, more than 
90% of these prescriptions were paid by some type of health insurance (e.g., commercial 
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insurance, Medicaid, Medicare, Workers’ compensation) (Table 2.2). Data on payer 
source for previous years were not available. On average, 161 per 1,000 residents had at 
least one opioid analgesic prescription dispensed each quarter in NMNAM counties 
(Table 2.2), a significantly higher rate compared with 104 per 1,000 for residents of the 
Metro counties. Residents of the Kentucky Appalachian region were prescribed opioid 
analgesics significantly more often than residents of Central Kentucky (156/1,000 vs 
108/1,000, respectively).   
2.3.2 Longitudinal Trends 
From the first quarter of 2012 (2012Q1) to the last quarter of 2015 (2015Q4), there 
was a 10% reduction in the unadjusted state rate of residents with opioid analgesic 
prescriptions (data not shown). The maps (Figure 2.2) demonstrate a visual decrease in 
the prescribing rate in the majority of the counties within the three geographical regions. 
In 2012Q1, the highest rates were observed in a group/cluster of counties in the 
southeastern part of the Kentucky Appalachian region. While this cluster shrank by 
2015Q4, a distinct group of neighboring counties in the core of the Appalachian region 
retained the highest rates (above 186/1,000). The tables next to each map provide 
comparison of the unadjusted rates in the three geographical regions (Appalachia, Delta, 
and Central) as well as the three rural-urban classification groups (Metro, NMAM, and 
NMNAM counties). The metropolitan counties had the lowest rates of residents with 
opioid analgesic prescriptions at baseline (113/1,000) and at the end of the study period 
(102/1,000) compared with the other rural-urban classification groups. 
 Figure 2.3 (by Region) shows parallel decreasing lines of the estimated adjusted 
rates of residents with dispensed opioid analgesic prescriptions for the three geographical 
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regions. The parallel lines indicate no significant variations in the magnitude of decrease 
in the rate of residents with opioid analgesic prescriptions from one quarter to the next 
among the 3 regions (non-significant by-time interaction with Region). The Appalachian 
region had a significantly higher baseline rate and despite the significant decline over 
time, it retained a significantly higher rate in 2015Q4 as evident by the confidence limit 
band (Figure 2.3, by Region). Due to the lack of significant by-time interaction, in any 
given quarter, the adjusted rate ratio (ARR) of opioid analgesic prescribing between the 
Appalachian region rate and the Central Kentucky region rate was 1.30 [95% CI: 1.20-
1.42], meaning the rate of Appalachian residents with opioid analgesic prescriptions was 
30% higher than the rate for Central Kentucky residents in any given quarter of the study 
period. The ARR between the Appalachian and the Delta regions was 1.19 [95% CI: 
1.06-1.33]. There was not enough evidence that the rate of residents with opioid analgesic 
prescriptions in the Delta region was significantly different from the Central Kentucky 
rate during any given quarter of the study period (ARR of 1.10 [95% CI: 1.00-1.21]).  
When looking at rural-urban county classification groups, the adjusted rate of 
opioid analgesic prescribing for the NMNAM counties was significantly higher at 
baseline (2012Q1) and remained significantly higher by the end of the study period 
(Figure 2.3, by Rurality). On average, in any given quarter, the rate of residents with 
opioid analgesic prescriptions in NMNAM counties was 33% higher than in Metro 
counties (ARR of 1.33 [95% CI: 1.22-1.45]) and 17% higher than in NMAM counties 
(ARR of 1.17 [95% CI: 1.07-1.29]).  
2.3.3 Factors Associated with High Rates of Opioid Analgesic Prescribing 
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The results from the adjusted models presented in Table 2.3 indicated potential 
risk or protective factors associated with the rate of residents with opioid analgesic 
prescriptions. The rate of ED visits due to acute injuries, the percentage of population 
aged 55 or older, and the percentage of noninstitutionalized civilians with health 
insurance were significantly and positively correlated with the modeled outcome. For 
every one-per thousand increase in the rate of ED visits due to acute injuries, the adjusted 
rate of residents with opioid analgesic prescriptions was estimated to increase 
multiplicatively by 1.0034 (increase by 3.4/1000). The rate of residents with 
buprenorphine/naloxone prescriptions and the percentage of population with a high 
school diploma were negatively associated with the outcome indicator. For instance, an 
average quarterly increase of one resident with buprenorphine/naloxone prescriptions per 
1,000 residents with opioid analgesic prescriptions was associated with a 0.1% reduction 
in the rate of residents with opioid analgesic prescriptions. The data did not support 
significant associations between the rate of residents with opioid analgesic prescriptions 
and percentage of white residents, median income, unemployment rate, rates of primary 
care physicians, rates of ED visits for treatment of heroin-related overdoses, rates of ED 
visits and inpatient hospitalizations involving non-cancer chronic pain, age-adjusted 
incidence rates of invasive cancer, or percentage of noninstitutionalized civilians with 
disability. 
2.4 Discussion 
The results from the longitudinal data analysis indicated a statistically significant 
declining trend in rates of residents with opioid analgesic prescriptions from 2012 to 
2015. This finding agreed with the hypothesis and was anticipated based on the national-
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level decrease in the rates of opioid analgesic prescriptions per capita, and the 
comprehensive efforts of Kentucky stakeholders to curtail the prescription opioid misuse 
and potentially inappropriate opioid analgesic prescribing in the state. However, direct 
comparison of these results with previous studies cannot be made as this is the first study, 
to the best of our knowledge, to measure the number of residents with opioid analgesic 
prescriptions rather than the number of opioid prescriptions. Because individual residents 
may have multiple opioid analgesic prescriptions simultaneously, measuring the number 
of residents with opioid analgesic prescriptions reflects more accurately the extent of 
prescription opioid analgesic use in the population.  
The changes in the number of residents with dispensed opioid analgesic 
prescriptions per capita over the study period were comparable (parallel) across 
geographical regions and across rural-urban classification groups. One interpretation of 
this finding is that the changes over time were driven by state and national policies and 
interventions41 that had a similar effect in different areas of the state. The rate of residents 
with opioid analgesic prescriptions in NMNAM counties was significantly higher at the 
beginning of the study and remained significantly higher at the end of the study period, 
regardless of the significant decline over time, and after controlling for health conditions 
justifying opioid analgesic prescribing. This finding is not surprising in that residents of 
remote rural counties do not have easy access to alternative non-opioid pain treatment 
options (e.g., interventional pain management, physical therapy)43 and, to the best of our 
knowledge, no significant progress has been made in the state to address these disparities. 
Additionally, the rate of medical conditions associated with pain (e.g., rate of acute 
injuries, percentage of population with disabilities; Table 2.2) remained more prevalent in 
22 
the NMNAM counties. The Delta and the Appalachian region are both predominantly 
rural, consisting mostly of NMNAM counties. The Kentucky Appalachian region was 
considered heterogeneous73 and the small grouping of counties adjacent to metropolitan 
areas were not typical for the Appalachian Mountains’ features. Residents living in the 
counties adjacent to metropolitan areas may not have limitations in accessibility to non-
opioid pain treatment options. Meanwhile, the large grouping of NMNAM counties in 
Kentucky Appalachia may make it very difficult for residents residing in the core of the 
Kentucky Appalachian region to access non-opioid pain treatment options usually 
available in large urban or metro centers. The hot spot of counties with a high number of 
residents on opioid analgesic prescriptions per capita in the center of the Appalachian 
region (Figure 2.2, 2015Q4) suggests that the geography and travel time/distance to 
medical centers could be important covariates that require further research to inform 
strategic development of specific interventions for these areas. Further research is needed 
to evaluate the options for non-opioid pain treatment in the Appalachian region (e.g., 
availability and accessibility of interventional pain management and physical therapy) as 
well as accessibility of and retention in medication treatment for opioid use disorder. In 
an effort to further improve opioid analgesic prescribing practices, the Attorneys General 
of Kentucky and West Virginia recently urged health insurers to modify their policies for 
pain management treatment to support use of non-opioid alternatives.74 
This study results suggest that increased buprenorphine/naloxone prescribing 
could be a significant factor for reducing opioid analgesic prescribing rates. The 
significant rise in the rate of residents with buprenorphine/naloxone combination 
prescriptions in Kentucky over the study period might be explained by several factors.  
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First, the Drug Addiction Treatment Act of 2000 (DATA 2000), which permitted 
qualified physicians to apply for a waiver to treat opioid use disorders with Schedule III - 
V medications specifically approved by the FDA for this indication, including 
transmucosal buprenorphine products, has increased access to outpatient treatment of 
opioid use disorder.75 Recent federal legislation now allows for physicians to treat up to 
275 patients concurrently (previous limit was 100 patients)76 with buprenorphine for 
opioid addiction treatment and also now allows qualified nurse practitioners to treat up to 
30 patients in the first year of their waiver and 100 thereafter.77 Second, Kentucky was an 
Affordable Care Act (ACA) expansion state which has been associated with increases in 
the supply of buprenorphine-waivered physicians in the US.78 Finally, the Kentucky 
Appalachian region (compared to the Central and Delta regions) historically has been 
noted to have high rates of residents with opioid use disorders and drug overdoses, 
indicating high demand for treatment.79  
Limiting prescription opioid analgesic supply to patients who have developed an 
opioid use disorder without providing evidence-based medical treatment for opioid 
addiction may result in shifting the demand for prescription opioids to heroin.13 A 
transition to heroin use cannot be ruled out as a possible factor for the declining rates of 
residents with opioid analgesic prescriptions in Kentucky based on the increasing number 
of heroin seizures reported by Kentucky State Police Crime Labs in recent years.80 
However, the rate of ED visits for treatment of heroin-related overdoses per 1,000 
residents as a proxy for heroin availability in a county was not significantly associated 
with the rate of residents with dispensed opioid analgesic prescriptions. 
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Another salient finding of this study was that counties with higher rates of ED 
visits due to acute injuries had higher rates of residents with opioid analgesic 
prescriptions. Injury prevention efforts and limiting the initial number of days’ supply for 
pain due to acute injury may have a positive effect on reducing exposure to opioids. 
Kentucky legislators took a step in this direction in 2017,81 requiring state professional 
licensing boards to promulgate regulations limiting prescriptions for Schedule II 
controlled substances for acute pain to a three-day supply, with certain exceptions. 
Consistent with a recent US Centers for Disease Control and Prevention (CDC) 
report,41 positive associations were found between rates of residents with opioid analgesic 
prescriptions and health insurance coverage. This result was understandable as the data 
indicated more than 90% of the opioid analgesic prescriptions in 2015 were paid by some 
type of health insurance. In addition, counties with higher percentages of population aged 
55 or older would be expected to experience higher rates of residents with opioid 
analgesic prescriptions because older people may need more frequent treatments with 
opioids for health conditions due to painful terminal illness.  
Lastly, these results should be interpreted in the context of residents with 
dispensed prescriptions for opioid analgesics rather than residents who used prescription 
opioids. Inferences cannot be made at the individual level due to limitations of the 
prescription drug monitoring program data which collects data on dispensed prescriptions 
but does not provide evidence that individuals receiving dispensed opioid analgesic 
prescriptions actually take the dispensed medication. Additionally, using proxy variables 
to measure medical needs for pain treatment, availability of medication treatment for 
25 
opioid use disorders, and availability of heroin may not reflect comprehensively these 
situations in practice.  
In conclusion, this study examined changes in the rate of residents with dispensed 
opioid analgesic prescriptions in Kentucky from 2012 to 2015 and identified no regional 
or rural/urban differences in the degree of decline over time. A significantly higher 
proportion of residents residing in the Kentucky Appalachian region or in NMNAM 
counties received prescriptions for opioid analgesics during the study period. These 
findings may be useful for modifying and tailoring local interventions, prescriber 
education, medical treatment capacity, and state policies to reduce potentially 
inappropriate opioid analgesic prescribing in Kentucky. The study also identified risk and 
protective factors for high rates of residents receiving opioid analgesic prescriptions, 
which may help prioritize and allocate resources and support to targeted groups in order 
to mitigate the opioid crisis in Kentucky. 
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component of the Department of Justice’s Office of Justice Program, which includes the 
Bureau of Justice Statistics, the National Institute of Justice, the Office of Juvenile Justice 
and Delinquency Prevention, the Office of Victims Crime, and the SMART Office. 
Viewpoints or opinions in this document are those of the authors and do not necessarily 
represent the official position or policies of the U.S. Department of Justice. 
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Table 2. 1. Measures and Data Sources 
Variables Data Sources 
Outcome variable: opioid analgesic prescribing rate 
(1) Rate of residents with opioid analgesic 
prescriptions per 1,000 residents 
The Kentucky All Schedule 
Prescription Electronic 
Reporting System 
(KASPER), Kentucky 
Office of Inspector General 
(OIG), 2012 – 2015 
Covariates 
(1) Percentage of population aged 55 or older 2011 – 2015 Five-Year 
Estimates American 
Community Survey (ACS) 
data, U.S. Census Bureau, 
2012 – 2015 
(2) Percentage of white residents 
(3) Median income 
(4) Percentage of population aged 25 or older with a 
high school diploma 
(5) Unemployment rate per population aged 16 or 
older 
(6) Percentage of noninstitutionalized civilians with 
health insurance 
(7) Rates of primary care physicians per 1,000 
residents 
County Health Rankings 
and Roadmaps, 2012 – 
2015 
(8) Rates of patients with buprenorphine/naloxone 
combination prescriptions per 1,000 residents with 
opioid analgesic prescriptions 
KASPER, OIG, 2012 – 
2015 
(9) Rates of ED visits due to acute injuries (excluding 
poisonings) per 1,000 residents 
Outpatient Claims data, the 
Kentucky Office of Health 
Data and Analytics 
(KOHDA), 2012 – 2015 
(10) Rates of ED visits for treatment of heroin-related 
overdoses per 1,000 residents 
(11) Age-adjusted incidence rates of invasive cancer 
averaged over the two years prior the year of 
modeled opioid prescribing per 1,000 residents 
Kentucky Cancer Registry, 
2010 – 2014 
(12) Rate of ED visits and inpatient hospitalizations 
involving non-cancer chronic pain per 1,000 
residents 
Inpatient Hospitalizations 
and Outpatient Claims data, 
KOHDA, 2012 – 2015 
(13) Percentage of noninstitutionalized civilians with 
disability 
ACS, U.S. Census Bureau, 
2012 – 2015 
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Table 2. 2. Characteristics of the Study Population by Region and Rurality: Kentucky 2012 – 2015 
Variable Region Rurality 
Delta Appalachian Central Metro NMAM NMNAM 
Number of counties 21 54 45 35 32 53 
Annual population 499,125 1,176,118 2,728,914 2,567,114 701,018 1,136,025 
Quarterly number of residents with 
analgesic opioid prescriptions 
65,952 182,935 293,393 268,215 91,040 182,426 
Quarterly rate of residents with 
opioid analgesic prescriptions per 
1,000 residentsa,b
132.14 155.54 107.51 104.48 129.87 160.58 
Percentage of population aged 55 
and oldera,b 
29.84 29.58 26.43 26.12 28.95 30.34 
Percentage of white residentsa,b 90.35 96.43 91.62 91.29 93.95 94.83 
Percentage of population aged 25 
and older with a high school 
diplomaa,b 
83.58 75.17 86.88 87.49 80.20 76.11 
Average median income (in $)* 25,553.19 23,467.65 27,557.18 28,657.76 24,816.53 23,524.39 
Unemployment rate per population 
aged 16 and older (%)a,b 
9.27 11.16 8.71 8.75 9.89 10.66 
Percentage of noninstitutionalized 
civilians with health insurancea,b 
86.11 84.39 87.88 87.95 85.54 84.79 
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Table 2.2 Continued 
Variable Region Rurality 
Delta Appalachian Central Metro NMAM NMNAM 
Rate of primary care physicians per 
100,000 residents* 
43.88 43.33 49.13 48.05 37.09 49.12 
Percentage of opioid analgesic 
prescriptions paid by a type of 
health insurance** 
91.47 91.41 93.40 93.34 93.16 90.96 
Quarterly rate of residents with 
buprenorphine/naloxone 
prescriptions per 1,000 residents 
with opioid analgesic 
prescriptionsa,b 
11.56 57.99 19.30 19.90 32.91 47.63 
Annual rate of ED visits for 
treatment of heroin-related 
overdoses per 100,000 residentsa,b 
0.65 10.12 53.93 54.89 19.97 3.96 
Quarterly rates of ED visits due to 
acute injuries (excluding 
poisonings) per 1,000 residentsa,b 
28.40 34.58 23.45 22.15 31.89 34.90 
Age-adjusted incidence rates of 
invasive cancer for 2010-2014 per 
100,000 residentsa,b 
481.04 539.60 520.92 516.67 536.97 522.41 
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Table 2.2 Continued 
Variable Region Rurality 
Delta Appalachian Central Metro NMAM NMNAM 
Quarterly rate of ED visits and 
inpatient hospitalizations involving 
non-cancer chronic pain per 1,000 
residentsa,b 
3.29 5.91 3.33 3.32 3.41 5.95 
Percentage of noninstitutionalized 
civilians with disabilitya,b 
16.78 22.72 14.34 14.15 18.62 21.87 
Note: Average values for the period between 2012 and 2015 by the groups of interest are given. 
*These values represent an average of the county-level measure by the groups of interest.
**These values were calculated for 2015 only. Data before 2015 were not available. 
aSignificant differences in at least one pair of the geographical regions (Regions)  
bSignificant differences in at least one pair of the rural-urban classification groups (Rurality) 
Abbreviations: NMAM: Non-metropolitan, adjacent to a metro area; 
NMNAM: Non-metropolitan, not adjacent to a metro area 
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Table 2. 3. Non-intercept Parameter Estimates for the Final Models of Rates of 
Residents with Dispensed Opioid Analgesic Prescriptions per 1,000 Residents: 
Kentucky 2012 – 2015 
Variables Model for Region Model for Rurality 
Coefficient p Coefficient p 
Region 
Delta 
Appalachian 
Central 
0.0916 
0.2645 
Reference 
.0597 
<.0001 
Not 
Applicable 
Rurality 
NMAM 
NMNAM 
Metropolitan 
Not 
Applicable 0.1235 
0.2847 
Reference 
.0032 
<.0001 
Time (in quarters) -0.0096 <.0001 -0.0093 <.0001 
Rate of ED visits due to 
acute injuries excluding 
poisoning per 1,000 
residents 
0.0034 <.0001 0.0034 <.0001
Percentage of 
noninstitutionalized 
civilians with health 
insurance 
1.1972 <.0001 1.2033 <.0001
Percentage of population 
aged 25 and older with a 
high school diploma 
-0.3560 .0477 -0.4196 .0182
Percentage of population 
aged 55 and older 
1.5915 .0009 1.3735 .0042
Rate of patients with 
buprenorphine/naloxone 
prescriptions per 1,000 
residents with opioid 
analgesic prescriptions 
-0.0010 <.0001 -0.0009 .0003 
Abbreviations: NMAM: Non-metropolitan, adjacent to a metro area;  
NMNAM: Non-metropolitan, not adjacent to a metro area
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Figure 2. 1. Kentucky’s Rural and Urban Areas 
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Figure 2. 2. Unadjusted Rates of Residents with Dispensed Opioid Analgesic Prescriptions per 1,000 Residents by 
County, Region, and Rurality: Kentucky 2012 and 2015 
 
 Counties that are non-metropolitan, adjacent to a metropolitan area (NMAM) or counties that are non-metropolitan, not 
adjacent to a metro area (NMNAM) cannot be identified easily on these maps. Please refer to Figure 2.1. 
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Figure 2. 3. Adjusted Rates of Residents with Dispensed Opioid Analgesic Prescriptions and Rate Ratios with 95% 
Confidence Limit Band by Region and Rurality, Kentucky 2012 - 2015 
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CHAPTER THREE 
Population-Level Measures for High-Risk Opioid Analgesic Prescribing: 
Longitudinal Trends and Relationships with Pain-Associated Conditions 
Abstract 
Objectives: The study objectives were to develop population-level measures for 
monitoring high-risk opioid analgesic prescribing and investigate their longitudinal 
associations with pain-associated conditions (acute traumatic injuries, chronic non-cancer 
pain, and cancer deaths).  
Methods: The study used Kentucky prescription monitoring data to calculate six 
measures of high-risk opioid analgesic prescribing: high daily morphine milligram 
equivalent dose, long-term opioid analgesic prescribing, long-term prescribing of high 
daily dose, concomitant opioid analgesics and benzodiazepine prescriptions, overlapping 
opioid analgesic prescriptions, and long-acting opioid analgesics prescribed to opioid-
naïve patients. Marginal models employed generalized estimating equations to evaluate 
the association over time between adjusted rates of high-risk opioid analgesic prescribing 
and rates of pain-associated conditions. 
Results: Statewide, high-risk opioid analgesic prescribing measure rates declined from 
2012 to 2016. Every 1/1,000-increase in the cancer death rate was significantly associated 
with 24/1,000, 17/1,000, and 16/1,000 increase in the adjusted annual rates of high-dose 
OA prescribing, long-term prescribing of high-dose opioid analgesics and opioid 
analgesic-benzodiazepine co-prescribing, respectively. Chronic non-cancer pain and 
acute traumatic injury rates were positively associated with high-risk opioid analgesic 
prescribing, but the association strength declined over time.  
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Conclusions: Rates of high-risk opioid analgesic prescribing were positively associated 
with cancer mortality rates with no substantial change in the association magnitude over 
time, suggesting recent clinical guidance for chronic non-cancer pain have not affected 
prescribing for cancer pain. Given evidence of no advantage of opioid analgesics over 
non- opioid analgesics for chronic non-cancer pain, decreasing high-risk opioid analgesic 
prescribing practices in the context of increasing chronic non-cancer pain rates is 
encouraging. Monitoring high-risk opioid analgesic prescribing trends is an important 
component of data-driven drug overdose prevention and enhanced public health 
surveillance. 
3.1 Introduction 
Reducing medically unnecessary exposure to opioid analgesics (OA) while 
ensuring their availability to patients who actually need them is a key public health 
objective in efforts to address the opioid crisis in the United States (US).82 The rise in OA 
prescribing over the last two decades, largely attributed to the treatment of chronic non-
cancer pain (CNCP), 83-87 has been associated with increasing rates of opioid-related 
overdoses, misuse and addiction in the US.9,39,88,89  Opioid prescribing in the context of 
CNCP has resulted in increases in not only the number and duration of OA prescriptions, 
but also the average daily morphine milligram equivalent (MME) dosages prescribed. 
Over a 10-fold dose escalation was commonly observed in patients with CNCP due to 
opioid tolerance.83,84 The use of high doses of OAs puts patients at higher risk of adverse 
effects, including opioid use disorder (OUD) and overdose, while the benefits appear 
limited as OA therapy has unsatisfactory effectiveness in CNCP management,90,91 even 
may cause hyperalgesia.92 Negative outcomes can be particularly severe (e.g., 
 
36 
 
unintentional overdose death) among patients with prescriptions for both OAs and other 
central nervous system depressants such as benzodiazepines, due to synergistic effects on 
respiratory depression. Notably, benzodiazepines and OAs are commonly co-prescribed 
for chronic pain relief.93-95 In addition, high-risk OA prescribing practices in the setting 
of acute pain, including prescribing for more than five days or initiating treatment with 
long-acting/extended-release (LA/ER) formulations instead of short-acting/immediate 
release (IR) formulations, can result in continued long-term use.96-98 Recent research on 
high-risk OA prescribing practices triggered re-evaluation within medical communities 
and enforcement by state-specific policies, including regulations with legal consequences 
to prescribers for violations.99,100 Prescribing guidelines for CNCP have been recently 
updated and promoted suggesting non-OA alternatives as a first-line treatment.101,102 
Current recommendations call for a limited days’ supply (3-7 days) of the initial OA 
prescription when used for acute, severe pain.103 Recommendations regarding OA use in 
chronic pain that is unresponsive to non-opioid therapy, and for cancer, palliative and 
end-of-life care call for initiation at the lowest effective dosage of IR formulations, with 
careful consideration of daily dosages greater than 90 morphine milligram equivalents 
(MMEs), and avoidance of concurrent use of multiple OAs, and OAs with 
benzodiazepines.102,104  
Therefore, monitoring trends in high-risk OA prescribing and understanding these 
trends in the context of cancer, CNCP, and acute pain prevalence and incidence are 
critical for developing and evaluating policy and practice for medically-justified OA 
prescribing. While recent studies have reported a reduction in the number of prescribed 
OAs and in high dosage prescribing,12,105 less is known about the changes of these and 
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other potentially risky OA prescribing practices in the context of changing rates of 
painful conditions traditionally treated with OAs.   
To address this gap, a set of high-risk OA prescribing measures was developed 
and longitudinal trends in high-risk OA prescribing in Kentucky from 2012 to 2016 were 
investigated. Additionally, the association of these measures with rates of CNCP, acute 
traumatic injuries and late-stage cancer over time was assessed, while controlling for 
time-varying county-level socio-economic and demographic factors, accessibility to 
opioid prescribers, availability of heroin, and rates of buprenorphine/naloxone (BP/N) 
prescribing as a measure for medication treatment for OUD. 
3.2 Methods 
3.2.1 Data Sources 
Kentucky’s prescription drug monitoring program (PDMP) data were used to 
compute high-risk OA and BPN prescribing indicators. Proxy measures for population-
based rates of painful conditions, traditionally treated with OAs, were defined by using 
Kentucky emergency department (ED) and inpatient hospital billing data, and death 
certificate data. County-level socio-economic status (SES) data were derived from the 
American Community Survey 5-Year Estimates, US Census Bureau,60 and primary health 
care provider density data were gathered from the County Health Rankings and 
Roadmaps.61  
3.2.2 Measures 
High-Risk OA Prescribing. OAs were defined as Schedule II to IV opioids, including 
methadone for pain, but excluding buprenorphine products used for medication treatment 
for OUD. MME dose calculation at the prescription level was based on the conversion 
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table and guidance developed by US Centers for Disease Control and Prevention 
(CDC).56 Daily cumulative MME dose at a person-level was calculated as the total MME 
from all OA prescriptions supplied for a given day.  
Based on existing clinical research and guidelines, six person-level measures for 
potentially high-risk OA prescribing were created: (1) High-dose OA prescribing 
(HDOAP) was defined as at least seven consecutive days (chosen to avoid 
misclassification due to early refills) with daily cumulative dose of 100 MME or more;106 
(2) Long-term OA prescribing (LTOAP) was defined as OA prescriptions for at least 90 
consecutive days’ supply;107 (3) Long-term high-dose OA prescribing (LTHDOAP) was 
defined as OA prescriptions for at least 90 consecutive days’ supply at an average daily 
cumulative MME dose of 100 or greater; (4) Concomitant prescribing of OAs and 
benzodiazepines (CPOAB) was defined as simultaneous prescriptions for both an OA and 
a benzodiazepine for at least seven consecutive days’ supply;108 (5) Concomitant 
prescribing of OAs (CPOA) was defined as at least seven consecutive days of two or 
more overlapping OA prescriptions;109 and (6) LA/ER OA prescribing (LAOAP) to an 
opioid-naïve person was defined as a LA/ER prescription dispensed to a person who had 
no prior OA prescription for at least 180 days.110 
Pain-Associated Conditions. To determine prescribing patterns within the context of 
potentially changing pain-associated condition prevalence, three pain-associated 
conditions traditionally treated with OAs were identified: acute traumatic injury, CNCP, 
and late-stage cancer. Rates of acute traumatic injuries were calculated using ED visit 
administrative claims and the CDC surveillance injury case definitions for ED data coded 
in the International Classification of Disease, Ninth Revision, Clinical Modification 
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(ICD-9-CM) before October 1, 2015, and the ICD-10-CM on and after October 1, 
2015.111 Inpatient hospitalizations and ED visits involving CNCP were identified by 
administrative billing records with any principal or secondary diagnosis of 338.21, 
338.22, 338.28, or 338.29 for ICD-9-CM-coded data,112 or any principal or secondary 
diagnosis of G89.21, G89.22, G89.28, or G89.29 for ICD-10-CM-coded data.113 Cancer 
death incidence (as proxy for late-stage cancer) was determined from death certificate 
data by any ICD-10 code for malignant neoplasms listed in the Comprehensive ICD-10 
Case Finding Code List for Reportable Tumors.114 
Covariates. County-level measures potentially associated with both OA prescribing 
outcomes and pain-associated condition measures included: (1) SES factors, including 
percentage of population aged 55 or older, percentage of white residents (excluding 
multiracial residents), median annual income, percentage of population aged 25 or older 
with a high school diploma, and unemployment rate; (2) proxy indicators for access to 
opioid prescribers, namely rate of primary care physicians per 1,000 residents, and 
percentage of noninstitutionalized civilians with health insurance coverage; (3) 
percentage of noninstitutionalized civilians with any disability; (4) a proxy for 
availability of medication treatment for OUD measured as the rate of residents with BP/N 
prescriptions per 1,000 residents with dispensed OA prescriptions; and (5) a proxy for 
heroin availability in a county measured as the rate of ED visits for treatment of heroin-
related overdoses per 1,000 residents.  
3.2.3 Statistical Methods 
Descriptive analyses included box plots and choropleth maps of annual county-
level rates of residents who meet the person-level criteria for each type of high-risk OA 
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prescribing per 1,000 residents (Figure 3.1 and 3.2), and scatterplots to visualize their 
relationship with painful condition rates in 2012 and 2016 (Figure 3.3 – Figure 3.9).  The 
strength of linear relationship between two variables was measured by a Pearson 
correlation coefficient (r). Percent change in median county-level OA prescribing rates 
from 2012 to 2016 was used as a measure of change.  
Generalized estimating equation (GEE) approach was used to determine the effect 
of time and pain-associated conditions on each OA prescribing measure. Negative 
binomial distribution was used to model the annual number of residents (counts) in each 
county who met the criteria for high-risk OA prescribing on a specific measure with 
adjustment for county population size by an offset (the logarithm of county population). 
An autoregressive working covariance structure was used because correlations of the 
outcome measurements tend to diminish over time. To investigate whether the strength of 
the association between pain-associated conditions and outcome measures varied over 
time, by-time interaction terms were included with each of the three pain-related 
conditions. Time-varying covariates described in section 3.2.2 were included in initial 
adjusted models. The inclusion of covariates in the final adjusted models was based on 
backward variable selection with a significance level of .05. Results are presented as 
parameter estimates with standard errors, representing the expected change in the log of 
the mean of the dependent variable for a one-unit change in a covariate (Table 3.1). To 
represent the interaction between time and pain-associated conditions, forest plots of 
estimated adjusted rate ratios (ARR) with 95% confidence intervals (CI) for a one-unit 
increase in the rate of a specific painful condition, in 2012 and 2016, are also provided 
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(Figure 3.10). Multi-collinearity was assessed by time-point using variance inflation 
factors; there was no evidence of multi-collinearity. 
SAS® 9.4 was used for all data management and statistical analyses. A two-sided 
significance level of .05 was used for all statistical tests. The choropleth maps were 
created with ArcGIS 10.4 (ESRI; Redland, CA). 
3.3 Results 
3.3.1 Trends in High-Risk OA Prescribing Rates and Pain-Associated Conditions 
Figure 3.1 describes the distribution of high-risk OA prescribing county-level 
measures by year.  From 2012 to 2016, there were decreases in the median annual rates 
on all measures: HDOAP (-35%), LTOAP (-6%), LTHDOAP (-30%), CPOAB (-26%), 
CPOA (-38%), and LAOAP (-33%). These reductions were confirmed with significant 
negative parameter estimates for time in unadjusted longitudinal analyses (GEE models 
with only time effect). 
The exposure variables of interest, rates of pain-associated conditions, were also 
analyzed for trend over time. There were no significant changes over the study period in 
the average county rate of acute traumatic injuries as well as the cancer death rate. 
However, there was a significant increase over time in the average county rate of CNCP 
(data not shown). 
3.3.2 Relationships of High-Risk OA Prescribing and Pain-Associated Conditions 
The scatterplots in Figure 3.3 provide an illustration of the relationship between 
the rates of pain-associated conditions and the high-risk OA prescribing measures. There 
was a general pattern of positive association, whereby as county annual rate for a pain-
associated condition increased, so did the county annual rate for a high-risk OA 
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prescribing measure. The linear relationship between each OA prescribing measure and 
the acute injury or the CNCP rates was strong (r≥0.5), with the exception of the LAOAP 
measure. The linear relationship between cancer rates and any OA prescribing measure 
was weak. The relationship between LAOAP and any of the three pain-associated 
conditions was very weak (absolute value of r<0.3). The scatterplots also suggest that 
strength of the association changed from 2012 to 2016. Despite the noticeable decrease in 
the overall level of high-risk OA prescribing measures from 2012 to 2016, the 2016 
scatterplots and the maps identified a group of rural, Appalachian Kentucky counties, 
with unusually high high-risk OA prescribing rates for the level of pain-associated 
condition rates (Figure 3.2 – Figure 3.9).  
Cancer Mortality. Cancer mortality was significantly positively associated with HDOAP, 
LTHDOAP and CPOAB, even after adjusting for other factors. The by-time interaction 
of the cancer death rate was not significant and the ARR estimates and 95% CI for each 
year were the same. On average, every 1/1,000 increase in the cancer death rate was 
associated with a 2.41%- increase in the adjusted rate of HDOAP (ARR 1.0241; 95% CI 
[1.0043 – 1.0442]), a 1.65%- increase in the adjusted rate of LTHDOAP, and a 1.61%- 
increase in the adjusted rate of CPOAB, throughout the study period (Figure 3.10). 
Acute Traumatic Injuries. There was a significant positive association between the rate of 
acute traumatic injuries and each of the six high-risk OA prescribing outcomes (Table 
3.1). The statistically significant by-time interactions of acute injury rates with negative 
directions in all models (except for LAOAP) indicated significant decreases in the 
strength of the positive relationships between these high-risk OA prescribing outcomes 
and the rate of ED visits for acute traumatic injuries over time. The modification of the 
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pain-associated condition and outcome relationship by year is demonstrated by 
comparing the ARR estimates for years 2012 and 2016 (Figure 3.10). For example, in 
2012, on average, every 1/1,000 increase in the acute injury rate was associated with a 
0.38%- increase in the adjusted rate of HDOAP (ARR 1.0038; 95% CI [1.0028 – 
1.0049]). In 2016, a 1/1,000 increase in the acute injury rate was associated with 
significantly lower increase in the rate of residents with high dose OA prescribing (ARR 
1.0015; 95% CI [1.0005 – 1.0025]). Despite the decreased association strength, there was 
still a significant positive association between rates of acute injury rates and high-risk OA 
prescribing outcomes in 2016 (2016 ARRs except for LTOAP were significantly above 1; 
Figure 3.10).   
Chronic Non-Cancer Pain. Rates of residents with CNCP were significantly associated 
with measures for HDOAP, LTHDOAP, and CPOA (Table 3.1). The magnitude of the 
associations declined over the study period, i.e. by-time interactions of CNCP rates in the 
adjusted models for these outcomes were significant with negative coefficients. The 2012 
estimates indicated that increases in the rate of CNCP were associated with increases in 
HDOAP, LTHDOAP, and CPOA, whereas the 2016 estimates suggested no relationship 
between the pain-associated conditions and the three outcomes (2016 ARRs were not 
significantly different from 1; Figure 3.10).  
3.4 Discussion 
All measures of high-risk OA prescribing examined in this study declined 
significantly in Kentucky from 2012 to 2016. The finding was expected in the context of 
the observed national- and state-level decreases in the volume of prescribed 
opioids12,75,115 and numerous interventions/policies implemented in Kentucky to reduce 
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overprescribing and misuse of prescription drugs, including opioids.53-55,116 Haffaiee et al. 
reported reductions in daily MME doses and percentages of patients receiving opioids 
from multiple providers in Kentucky after implementation of a robust PDMP in 2012.105 
The decrease in the high-risk OA prescribing rates in Kentucky could also be a reflection 
of the required continuing education for controlled substance prescribers in Kentucky, 
mandated under Kentucky HB1 in 2012.52 It is important for professional groups to 
provide training, including updates on pain management guidelines to primary care 
physicians as previous evidence suggested that most are not well-trained in recognizing 
drug-seeking behaviors, in identifying and treating OUD, and often face time constraints 
in evaluation and follow-up of patients with complicated chronic pain.45  
Despite the overall decreasing trend, unusually high rates of residents with high-
risk OA prescribing in a group of counties in Eastern Kentucky, in the center of the 
Kentucky Appalachian region, were observed. It is necessary for Kentucky public health 
researchers and agencies to examine the reasons for this finding as well as investigate the 
possible need for targeted education and interventions among prescribers serving these 
geographical areas. It has been noted that physicians serving residents of these counties 
do not have many non-opioid options for pain management.115 It is also possible that the 
high rates are an indication of a high proportion of residents dependent upon opioids yet 
not receiving treatment for OUD, and seeking opioids by presenting at health care 
facilities with complains for acute or chronic pain.  
The cancer mortality rate was significantly and positively associated with rates of 
HDOAP, LTHDOAP and CPOAB, with no substantial change in the association 
magnitude over time. This finding aligns with current clinical practice guidelines that 
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continue to recommend OA therapy for the management of severe pain in the setting of 
cancer and palliative care.117  
In contrast, a decline in the strength of positive relationships between both acute 
traumatic injury and CNCP rates with high-risk OA prescribing rates over time was 
noted. By 2016, rates of CNCP were no longer significantly associated with the high-risk 
opioid prescribing measures. Weak evidence about the effectiveness of opioid treatment 
for CNCP over the last decade,118 evidence about opioid misuse, dependence and 
addiction as a result of long term opioid prescribing for CNCP,119-122 increased 
understanding for the benefit of non-opioid alternative for CNCP treatment (e.g., 
interventional pain management),123,124 and recent guidelines for opioid prescribing in 
CNCP treatment101,125 may have contributed to these changes. While an upward trend in 
CNCP was found, this finding is encouraging as research showed no more benefit of OAs 
versus non-OAs for CNCP.126 
This study found that LTOAP rates in Kentucky counties were not significantly 
associated with rates of CNCP rates in 2012. This could be due to studies and 
professional associations’ papers on limited effectiveness of long-term opioid prescribing 
on CNCP management. However, LTOAP rates in Kentucky were significantly 
associated with acute injury rates in 2012. There are emerging evidence that long-term 
use of OAs is often a result of initial OA prescribing for acute pain.127 Some states have 
limited initial opioid prescribing for acute pain.103 In 2017, Kentucky enacted regulations 
that limited Schedule II OA prescriptions for acute pain to a 3-day supply (with some 
exceptions).81 
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One limitation of this study is that the PDMP data represent dispensed 
prescriptions rather than actual utilization by patients. Another limitation is that claim 
data cannot be linked at patient-level to identify the diagnosis justifying the prescribing 
of a dispensed OA. In addition, the rates of acute traumatic injuries and CNCP reflect 
instances of ED visits and inpatient hospitalizations, rather than distinct patients. 
Kentucky state data policy requires removal of personal identifiers from state 
administrative billing data sets, so transfers from one hospital to another, readmission for 
active treatment of the same injury/condition, or linkage with PDMP data are not 
possible.  
3.5 Conclusions 
 This study used PDMP data to evaluate longitudinal trends in multiple measures 
for population-level high-risk OA prescribing practices. A multitude of mortality and 
morbidity surveillance data were utilized to advance the understanding of these trends in 
the context of changing pain-associated conditions, and other risk and protective factors. 
The findings can be used to inform policy, education, research, and drug overdose 
prevention interventions. Additionally, the findings from this study may stimulate interest 
in establishing consensus measures for monitoring high-risk OA prescribing and 
enhancing state public health surveillance systems for drug overdose prevention with 
population-level PDMP data indicators. Continued tracking of trends in high-risk OA 
prescribing measures is an important component of data-driven public health efforts to 
promote safer opioid prescribing and co-prescribing.  
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Figure 3. 1. Unadjusted County Rates of Residents with High-Risk Opioid Analgesic 
Prescribing by Year, Kentucky 2012 – 2016  
 
Note: GEE models to assess the effect of time indicated a negative and significant association (p<.0001).
Abbreviations: HDOAP = Rate of high-dose opioid analgesic prescribing; LTOAP = Rate of long-term opioid analgesic
prescribing; LTHDOAP = Rate of long-term high-dose opioid analgesic prescribing; CPOAB = Rate of concomitant
prescribing of opioid analgesics and benzodiazepines; CPOA = Rate of concomitant prescribing of opioid analgesics;
LAOAP = Rate of long-acting opioid analgesic prescribing for opioid-naive patients. All rates are annual county counts
per 1,000 residents.
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Figure 3. 2. Unadjusted Annual Rates of Residents with High-Risk Opioid Analgesic 
Prescribing by County, Kentucky 2012 and 2016 
 
 
Abbreviations: HDOAP = Rate of high-dose opioid analgesic prescribing;  LTOAP = Rate of long-term opioid analgesic prescribing; 
LTHDOAP = Rate of long-term high-dose opioid analgesic prescribing; CPOAB = Rate of concomitant prescribing of opioid analgesics 
and benzodiazepines; CPOA = Rate of concomitant prescribing of opioid analgesics; LAOAP = Rate of long-acting opioid analgesic
prescribing for opioid-naive patients. All rates are annual county counts per 1,000 residents.
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Figure 3. 3. Bivariate Relationships of High-Risk Opioid Analgesic Prescribing 
Rates with Pain-Associated Conditions, Kentucky 2012 and 2016 
Notes: All rates are annual county counts per 1,000 residents. All p values for the Rho estimates are less than a signif icance level of .05, except for the
Rho estimates of LAOAP.
Abbreviations: HDOAP = Rate of high-dose opioid analgesic prescribing; LTOAP = Rate of long-term opioid analgesic prescribing; LTHDOAP = Rate of
long-term high-dose opioid analgesic prescribing; CPOAB = Rate of concomitant prescribing of opioid analgesics and benzodiazepines; CPOA = Rate of
concomitant prescribing of opioid analgesics; LAOAP = Rate of long-acting opioid analgesic prescribing for opioid-naive patients; r(2012) = Pearson
correlation coeff icient (Rho) for 2012 data; r(2016) = Pearson correlation coeff icient (Rho) for 2016 data.
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Figure 3. 4. Bivariate Relationships of High-Dose Opioid Analgesic Prescribing Rates with Pain-Associated Conditions, 
Kentucky 2016 
 
Notes: All rates are annual county counts per 1,000 residents
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Figure 3. 5. Bivariate Relationships of Long-Term Opioid Analgesic Prescribing Rates with Pain-Associated 
Conditions, Kentucky 2016 
 
Notes: All rates are annual county counts per 1,000 residents
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Figure 3. 6. Bivariate Relationships of Long-Term High-Dose Opioid Analgesic Prescribing Rates with Pain-Associated 
Conditions, Kentucky 2016 
 
Notes: All rates are annual county counts per 1,000 residents
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Figure 3. 7. Bivariate Relationships of Rates of Concomitant Prescribing of Opioid Analgesics and Benzodiazepines 
with Pain-Associated Conditions, Kentucky 2016 
 
Notes: All rates are annual county counts per 1,000 residents
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Figure 3. 8. Bivariate Relationships of Rates of Concomitant Prescribing of Opioid Analgesics with Pain-Associated 
Conditions, Kentucky 2016 
 
Notes: All rates are annual county counts per 1,000 residents
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Figure 3. 9. Bivariate Relationships of Long-Acting Opioid Analgesic Prescribing Rates with Pain-Associated 
Conditions, Kentucky 2016 
 
Notes: All rates are annual county counts per 1,000 residents
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Figure 3. 10. Adjusted Rate Ratio by Pain-Associated Conditions, Kentucky 2012 and 2016 
 
The adjusted rate ratios (ARRs) of the outcome indicators are for a one-unit increase in the rates of the pain conditions (one per 1,000 residents). The blank plots indicate non-significant associations.
Abbreviations: HDOAP = Rate of high-dose opioid analgesic prescribing; LTOAP = Rate of long-term opioid analgesic prescribing; LTHDOAP = Rate of long-term high-dose opioid analgesic prescribing;
CPOAB = Rate of concomitant prescribing of opioid analgesics and benzodiazepines; CPOA = Rate of concomitant prescribing of opioid analgesics; LAOAP = Rate of long-acting opioid analgesic prescribing
for opioid-naive patients.
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Table 3. 1. Non-Intercept Parameter Estimates with Standard Errors from the Final Models 
Variable HDOAP LTOAP LTHDOAP CPOAB CPOA LAOAP 
Time -0.0249 
(0.0181) 
0.0103 
(0.0115) 
-0.0389* 
(0.0175) 
-0.0546*** 
(0.0136) 
-0.0455* 
(0.0180) 
-0.1071*** 
(0.0099) 
Rate of ED visits due to acute traumatic 
injuries per 1,000 residents 
0.0038*** 
(0.0006) 
0.0012** 
(0.0004) 
0.0030*** 
(0.0006) 
0.0019*** 
(0.0004) 
0.0046*** 
(0.0005) 
0.0018* 
(0.0009) 
Rate of ED visits and inpatient 
hospitalizations involving CNCP per 
1,000 residents 
0.0070*** 
(0.0017) 
___ 0.0072** 
(0.0021) 
___ 0.0065*** 
(0.0017) 
___ 
Rate of cancer mortality per 1,000 
residents 
0.0238* 
(0.0100) 
___ 0.0164* 
(0.0077) 
0.0160*   
(0.0076) 
___ ___ 
By-time interaction of the rate of ED 
visits due to acute traumatic injuries 
-0.0006*** 
(0.0001) 
-0.0003** 
(0.0001) 
-0.0003* 
(0.0001) 
-0.0003** 
(0.0001) 
-0.0004* 
(0.0002) 
___ 
By-time interaction of the rate of ED 
visits and inpatient hospitalizations 
involving CNCP 
-0.0022*** 
(0.0005) 
___ -0.0018** 
(0.0005) 
___ -0.0014** 
(0.0005) 
___ 
By-time interaction of the rate of 
cancer mortality 
___ ___ ___ ___ ___ ___ 
Percentage of population aged 55+ ___ ___ -1.7982** 
(0.6254) 
1.6171**       
(0.6047) 
___ ___ 
Percentage of white residents 1.6801*** 
(0.3495) 
___ 2.2306*** 
(0.5042) 
1.3075*         
(0.5127) 
0.8265** 
(0.3171) 
___ 
Median income (in $100) ___ ___ ___ -0.0009*        
(0.0004) 
___ ___ 
Percentage of population aged 25+ 
with a high school diploma 
___ -0.7687** 
(0.2901) 
-0.9748** 
(0.3742) 
-0.9398**      
(0.3271) 
-1.4770** 
(0.4625) 
___ 
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Table 3.1 Continued 
Variable HDOAP LTOAP LTHDOAP CPOAB CPOA LAOAP 
Unemployment rate per population 
aged 16+  
1.0857* 
(0.4501) 
-0.5603* 
(0.2210) 
1.0883* 
(0.5140) 
___ 1.1225* 
(0.5338) 
___ 
Percentage of noninstitutionalized 
civilians with health insurance 
1.9595*** 
(0.3499) 
0.7918* 
(0.3185) 
1.7044*** 
(0.4077) 
1.5617***      
(0.2633) 
1.0961* 
(0.5213) 
___ 
Rate of primary care physicians per 
1,000 residents 
0.1457** 
(0.0559) 
___ ___ ___ 0.1388* 
(0.0616) 
___ 
Percentage of noninstitutionalized 
civilians with disability 
___ ___ ___ 0.9856* 
(0.4031) 
1.4907** 
(0.4726) 
___ 
Rate of residents with BPN 
prescriptions per 1,000 residents with 
OA prescriptions 
___ ___ ___ ___ -0.0021** 
(0.0007) 
___ 
Rate of ED visits for treatment of 
heroin-related overdoses per 1,000 
residents 
___ ___ ___ ___ -0.0689*** 
(0.0181) 
___ 
*p<.05  **p<.01    ***p<.0001   ___ Not significant and excluded from the final model 
Standard Errors (SE) are given in the parentheses. 
Abbreviations: BPN = buprenorphine/naloxone; CNCP = chronic non-cancer pain; ED = emergency department; OA = opioid 
analgesic; HDOAP = high-dose opioid analgesic prescribing; LTOAP = long-term opioid analgesic prescribing; LTHDOAP = 
long-term high-dose opioid analgesic prescribing; CPOAB = concomitant prescribing of opioid analgesics and 
benzodiazepines; CPOA = concomitant prescribing of opioid analgesics; LAOAP = long-acting opioid analgesic prescribing 
for opioid-naive patients. 
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CHAPTER FOUR 
A Reciprocal Association between Longitudinal Trends of Buprenorphine/Naloxone 
Prescribing and High-Dose Opioid Analgesic Prescribing 
Abstract 
Introduction: Buprenorphine/naloxone (BP/N) treatment is a highly effective treatment 
for opioid use disorder decreasing illicit opioid use and both all-cause and opioid-
involved overdose mortality. Few studies have examined how the expansion of BP/N 
treatment affects opioid analgesic prescribing and vice versa. The purpose of this study 
was to investigate the relationships between BP/N prescribing and high-dose opioid 
analgesic prescribing (HDOAP) over time. 
Methods: This longitudinal study used Kentucky All Schedule Prescription Electronic 
Reporting data, 2012-2017, and cross-lagged structural equation analysis to evaluate the 
relationship between rates of residents with BP/N prescriptions and rates of residents with 
HDOAP (per 1,000 residents with opioid analgesic prescriptions) in relation to baseline 
socioeconomic status, medical needs for OAs, and heroin availability. HDOAP at the 
person-level was defined as at least seven consecutive days with a daily cumulative dose 
of 100 morphine milligram equivalents or more. For each quarter-county observation, 
HDOAP rate was used to predict BP/N prescribing rate at the next quarter, and 
simultaneously BP/N prescribing rate was used to predict HDOAP at the next quarter.  
Results: On average, HDOAP rates in Kentucky decreased by more than 10% (p<.0001) 
and BP/N prescribing rate increased by more than 5% (p<.0001) per quarter over the 
study period. Every one-per-thousand higher HDOAP rate in an earlier quarter was 
associated with a 0.01/1,000 increase in the BP/N prescribing rate in a later quarter (p= 
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.009). Conversely, a one-unit higher BP/N prescribing rate in an earlier quarter was 
associated with a 0.01/1000 reduction in the HDOAP rate in a subsequent quarter 
(p=.017). 
Conclusions: The results indicate a significant reciprocal relationship between HDOAP 
and BP/N prescribing, and a clinically meaningful effect of BP/N prescribing on reducing 
opioid analgesic prescribing. Future studies on BP/N treatment expansion should take 
into account this bi-directional association in the context of longitudinal data and evaluate 
for public health benefits beyond the reduction of HDOAP. 
4.1 Introduction 
The opioid crisis in the United States has been attributed to over-prescribing 
opioid analgesics (OAs), including inappropriate high-dose OA prescribing (HDOAP).1 
Patients receiving higher daily morphine-equivalent dosages were more likely to develop 
an opioid use disorder (OUD), to transition to heroin, or to experience an overdose.2,15,128-
130 To address the opioid epidemic, reducing risky prescribing practices to prevent new 
cases of OUD and related harms should be accompanied by increased OUD treatment for 
those already dependent. Research shows that without adequate access to OUD treatment, 
patients with OUD may transition to the illicit drug market, which is associated with 
higher risk of overdose.131 Thus, expanding the availability of effective OUD treatment is 
necessary given that approximately 80% out of 2.1 million Americans with OUD have 
not received evidence-based treatment.132 
Methadone (an opioid agonist) and buprenorphine (a partial opioid agonist) have 
been approved by the Food and Drug Administration (FDA) as effective treatments for 
OUD,133,134 and are also included on the World Health Organization’s list of essential 
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medications.135 While methadone can be only distributed through licensed opioid 
treatment programs in the United States, buprenorphine can be prescribed by qualified 
physicians and other practitioners with a waiver to treat OUD in outpatient settings, under 
the Drug Addiction Treatment Act of 2000 (DATA 2000).57,136 Due to federal restrictions 
on methadone treatment, expansion of buprenorphine has been a critical way to increase 
access to medication treatment for OUD. As a partial mu-opioid agonist, buprenorphine, 
including buprenorphine/naloxone (BP/N), has an improved safety profile over full mu-
opioid agonists, and has been demonstrated to decrease illicit opioid use as well as all-
cause and opioid-related overdose mortality.137,138 A significant concern related to 
expanding buprenorphine treatment is the inadequacy of counseling and social support, 
which may lead to drug diversion and misuse.139-142 However, research has demonstrated 
that attempting but failing to enter into legitimate buprenorphine treatment is associated 
with increased risk of using diverted buprenorphine.143,144 Furthermore, BP/N diversion 
continues to rise where accessibility to treatment remains limited.144 Given that large 
studies have demonstrated that buprenorphine is associated with decreased opioid-
involved overdose deaths and all-cause mortality137,138 even in a background of ongoing 
buprenorphine diversion, it is important that access to buprenorphine treatment not be 
curtailed142,145 and that further treatment expansion be seen as an actionable transforming 
step in a long-term battle against the opioid crisis.146-149 
Despite a significant increase in buprenorphine prescribing,150,151 the annual 
growth in buprenorphine distribution has not met its accelerating demand.152 Along with 
logistic and financial barriers,153-155 there is also ongoing stigma surrounding OUD, the 
people with this illness, and its medication treatments.156,157 Few studies have examined 
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how expansion of BP/N treatment affects OA prescribing and vice versa. To fill this gap, 
this study measured population-level indicators for HDOAP and BP/N prescribing using 
prescription drug monitoring program (PDMP) data, and investigated the reciprocal 
relationships between BP/N prescribing and HDOAP over time. The hypothesis was that 
HDOAP will positively predict BP/N prescribing, and simultaneously BP/N prescribing 
will negatively predict HDOAP, after adjusting for baseline differences in socio-
economic status (SES) characteristics, medical needs for OAs, and heroin availability.  
4.2 Conceptual Framework 
A conceptual framework that hypothesizes a mechanism for a reciprocal 
relationship between HDOAP and BP/N prescribing at the county level was developed 
(Figure 4.1). HDOAP in an earlier quarter may be associated with increased BP/N 
prescribing in a subsequent quarter because increased high-dose OA prescribing is 
associated with increased risk of OUD,5,158,159 which may result in increased demand for 
BP/N treatment. Simultaneously, BP/N prescribing in an earlier quarter may be 
associated with decreased HDOAP in a subsequent quarter as patients receiving BP/N 
treatment for OUD may not continue seeking prescription OAs.160  
Multiples factors related to the hypothesized relationship were identified from the 
literature, including SES, medical needs for OAs (i.e., the prevalence and incidence of 
painful conditions traditionally treated with OAs), and availability of heroin. Non-
metropolitan counties, typically characterized by lower SES relative to metropolitan 
counterparts, are more likely to have higher traumatic injury, comorbidity, and cancer 
rates,161 and more limited access to OUD treatment,162,163 but may be less exposed to 
heroin.164 Consequently, non-metropolitan county status is significantly associated with 
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higher OA prescribing.41,115 Rates of painful conditions, such as acute traumatic injuries, 
chronic non-cancer pain (CNCP), or late-stage cancer, are substantially and positively 
associated with OA prescribing.41,115,165 Concerns highlighted in previous research 
suggest that limiting OA prescriptions (supply) without providing adequate capacity for 
OUD treatment (to reduce the demand) may result in a transition to heroin.13 How 
increased heroin availability in communities affects the volume of dispensed OAs or 
BP/N has been not well-established. 
4.3 Methods 
4.3.1 Measurements and Data Sources 
Measures for HDOAP and BP/N prescribing were determined from Kentucky’s 
PDMP data, known as the Kentucky All Schedule Prescription Electronic Reporting 
(KASPER) program, Office of Inspector General (OIG), Cabinet for Health and Family 
Services. HDOAP at the person level was defined as at least seven consecutive days with 
a daily cumulative dose of 100 morphine milligram equivalents or more. BP/N 
prescribing at the person-level was determined as at least one BP/N prescription 
dispensed to a person. The two prescribing measures were aggregated at the county level 
for a quarter, and adjusted for the OA utilization in the county for that quarter. 
Specifically, the two measures of interest were defined as: (1) quarterly county rate of 
residents with HDOAP per 1,000 residents with OA prescriptions; and (2) quarterly 
county rate of residents with BP/N per 1,000 residents with OA prescriptions.  
As described in the Conceptual Framework, county-level factors that may 
potentially affect the relationship between rates of HDOAP and BP/N prescribing are 
SES, medical needs for OAs, and heroin availability. A dichotomized variable for county 
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metropolitan status was created using the U.S. Department of Agriculture Economic 
Research Service (ERS) Rural-Urban Continuum Code (RUCC) 2013 (RUCC codes 1 – 
3 for metropolitan counties, and RUCC codes 4 – 9 for non-metropolitan counties).62 
Baseline proxy measures for prevalence and incidence of pain conditions that have been 
treated traditionally with OAs were (1) rates of emergency department (ED) visits due to 
acute traumatic injury for the first quarter of 2012, which were calculated from ED visit 
claim data, provided by the Kentucky Office of Health Data and Analytics, (2) rates of 
inpatient hospitalizations and ED visits involving CNCP for the first quarter of 2012, 
computed from ED visits and inpatient hospitalizations claim data, and (3) rates of cancer 
deaths in 2012, identified from death certificate data, provided by the Kentucky Office of 
Vital Statistics. Heroin availability in a county was measured as the rate of county 
resident ED visits for treatment of heroin-related overdoses per 1,000 residents in 2012. 
4.3.2 Statistical Analyses 
Descriptive Analysis. The state-wide trends in the quarterly HDOAP and BP/N 
prescribing rates are demonstrated in a line graph (Figure 4.2). The geographical 
distributions of county-level HDOAP and BP/N prescribing rates are visualized with 
choropleth maps created in ArcGIS 10.4 package at baseline (the first quarter of 2012) 
and at the end of the study period (the fourth quarter of 2017). Same breaks with four 
levels were used for classifying the prescribing measures at baseline and end of the study 
period (Figure 4.3). 
Cross-Lagged Structural Equation Analysis. Structural equation modeling (SEM) was 
used to build and evaluate the network of relationships between HDOAP and BP/N 
prescribing, accounting for the above-mentioned factors at baseline. The initial full model 
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was based on the predefined conceptual framework (Figure 4.1). To examine the 
hypothesized reciprocal relationship between HDOAP and BP/N prescribing across 24 
quarter time points from 2012 to 2017, a cross-lagged panel approach was 
employed.166,167 For each lag, the HDOAP rate at an earlier quarter was used to predict 
BP/N prescribing rate at the subsequent quarter, and simultaneously BP/N prescribing 
rate in an earlier quarter was used to predict HDOAP at the subsequent quarter. One 
assumption of the cross-lagged panel analysis is that relationship stays the same over 
time.167 Therefore, the coefficient estimates for each direction of the bi-directional 
relationship were constrained to be the same across the time points. Autoregressive 
coefficients for correlations of each variable within time-points (i.e. correlations between 
a HDOAP rate at an earlier quarter and a HDOAP rate at the subsequent quarter, or 
correlations between a BP/N prescribing rate at an earlier quarter and a BP/N prescribing 
rate at the subsequent quarter) were controlled for stability over time. Other variables and 
paths that were potentially related to the relationship between HDOAP and BP/N 
prescribing were specified with a temporal flow to ensure that exposures at an earlier 
time point were used to predict outcomes at a later time point. For example, the HDOAP 
rate at the first quarter of 2012 was used to predict an annual rate of heroin-related ED 
visits at the end of 2012, or the annual rate of heroin-related ED visits in 2012 was used 
to predict BP/N prescribing at the first quarter of 2013.  
A stepwise variable and pathway selection was performed for model building. 
The variable or link with the highest p-value above .10 level and/or not plausible was 
dropped, and the model was re-evaluated for the next candidate variable/link to be 
dropped. When the parsimonious model was reached, plausible variables or parameters 
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having large modification indices (MI) were added back to the models one-by-one by 
reassessing model fit by the MI cut-off-point of 3.84 and over.168 The goodness-of-fit 
statistics of the final model was evaluated by the Root Mean Square Error of 
Approximation (RMSEA), the Comparative Fit Index (CFI) and the Tucker-Lewis Index 
(TLI).169,170 Directions with coefficient estimates, standard errors, and p-values from the 
final model were presented in Figure 4.4.  
Additionally, in order to determine the dominant direction of the reciprocal 
relationship between HDOAP and BP/N prescribing, standardized regression coefficients 
were obtained for both directions from fitting the final model with the HDOAP and BP/N 
prescribing rates that were standardized by the grand mean and standard deviation for all 
time points. 95% confidence intervals (CI) for the estimated standardized coefficients for 
each direction of the relationship between HDOAP and BP/N prescribing were computed 
(Table 4.1) and the absolute values of the two CI limits were compared. If the 95% CIs 
for the absolute values do not overlap, there is a significant difference between the 
absolute value of the two standardized coefficients, suggesting that one direction of the 
relationship is significantly stronger, predominant than the other direction. 
Data management and descriptive analyses were conducted using SAS® 9.4. 
Mplus (Version 7) was used for the cross-lagged structural equation analysis. 
4.4 Results 
4.4.1 Descriptive Results 
The line graph shows a declining trend in the HDOAP rates and an increasing 
trend in the BP/N prescribing rates at state level from the first quarter of 2012 to the 
fourth quarter of 2017 (Figure 4.2). At the state level, on average, for every 1,000 
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residents with OA prescriptions, there were 75 residents with HDOAP and about 20 
residents with BP/N prescribing in the first quarter of 2012. By the end of the study 
period, the last quarter of 2017, there were less than 50 residents with HDOAP and 
almost 70 residents with BP/N prescribing. 
 The choropleth map for HDOAP shows that in a fourth of the Kentucky counties, 
more than 1 out of 10 residents with OA prescriptions were prescribed with at least 100 
MME OAs for seven consecutive days or more (rates of >100/1,000) (Figure 4.3). By the 
last quarter of 2017, only 11 out of the 120 counties had a HDOAP rate higher than 
60/1,000. The BP/N prescribing rates increased in the majority of Kentucky counties 
from the first quarter of 2012 to the fourth quarter of 2017. Figure 4.3 also indicates a 
considerable decline in the HDOAP rates in Kentucky Appalachian counties during the 
study period with a substantial concurrent increase in the BP/N prescribing rates. 
4.4.2 A Relationship between HDOAP and BP/N Prescribing 
Figure 4.4 presents coefficient estimates corresponding to the examined directions 
(with standard errors in parenthesis). For example, the coefficient for the relationship 
between HDOAP at the first quarter of 2012 and BP/N prescribing rate at the second 
quarter of 2012 (and any consecutive quarters) is 0.012 (p=.009), indicating that on 
average, every one-per-thousand higher HDOAP rate in an earlier quarter was associated 
with a significant, 0.012/1,000 increase in the BP/N prescribing rate in a later quarter. In 
other words, for every additional 1,000 residents with HDOAP in an earlier quarter, the 
mean change in BP/N prescribing was estimated to increase by 12 residents in the 
subsequent quarter. Alternatively, the coefficient for the relationship between BP/N 
prescribing at the first quarter of 2012 and HDOAP at the second quarter of 2012 is -
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0.006 (p=.017) and remains the same for any subsequent lag of measures. This means 
that a one-unit increase in the BP/N prescribing rate in an earlier quarter was associated 
with a significant, 0.006/1,000 reduction in the HDOAP rate in a subsequent quarter. For 
example, for each additional 1,000 residents with BP/N prescribing in an earlier quarter, 
the mean change in HDOAP was estimated to decrease by six residents in the subsequent 
quarter. 
Table 4.1 shows that the effect size of the direction from BP/N prescribing to 
HDOAP was higher than the opposite direction in terms of absolute value, -0.013 versus 
0.005, respectively. However, a significant difference in the effects size of the two 
directions could not be concluded because the 95% CIs for the absolute values of the 
estimated effect size overlapped (95% CI for the absolute value of the effect size for 
“BP/N prescribing HDOAP”: [0.001; 0.025]; 95% CI for the absolute value of the 
effect size for “HDOAP BP/N prescribing”: [0.001; 0.009]). Thus, a significantly 
dominant direction in the bi-directional relationship could not be established. 
The autoregressive coefficient estimates of HDOAP representing correlations of 
HDOAP within time-points suggest that HDOAP rates decreased by more than 10% per 
quarter (β= 0.898, p <.0001; Figure 4.4). The autoregressive coefficient estimates of 
BP/N prescribing rate are 1.049 (p <.0001; Figure 4.4) for every lag, indicating that the 
BP/N prescribing rate increased by more than 5% per quarter over the study period. 
4.4.3 Other Relationships 
Metropolitan counties were associated with lower on average BP/N prescribing 
rate (-8.511/1,000; p=.002) compared with non-metropolitan counties, and lower CNCP 
rates (-1.48/1,000; p=.003), but higher rates of heroin-related ED visits (0.165/1,000; 
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p<.0001). Counties with one unit (i.e., 1/1,000) higher in the CNCP rates experienced 
2.35/1,000 higher in the quarterly HDOAP rates (p=.002). No significant associations 
between acute traumatic injury rates or cancer death rates with HDOAP were found. 
Every one unit (1/1,000) increase in the county quarterly HDOAP rate was associated 
with a 0.003/1,000 increase in the annual heroin overdose ED visit rate (p=.008).  One 
unit (1/1,000) increase in the heroin annual overdose ED visit rate was associated with a 
2.4 units decrease (-2.40/1,000) in the BP/N prescribing rate (p=.043). A significant 
pathway from the rates of BP/N prescribing to the rates of heroin-related ED visits was 
not observed. 
The goodness-of-fit statistics of the final model, including the Root Mean Square 
Error of Approximation (RMSEA) that was less than .05, and the Comparative Fit Index 
(CFI) and Tucker-Lewis Index (TLI) that were greater than 0.90, shows that there was 
not enough evidence to conclude that the model did not fit well.  
4.5 Discussion 
A significant reciprocal relationship between HDOAP and BP/N prescribing was 
found, after adjusting for baseline differences in SES characteristics, medical need for 
OAs, and heroin availability. This study provided population-level evidence of a 
meaningful effect of BP/N prescribing on reducing high-dose OA prescribing. The 
finding agreed with the hypothesis that HDOAP would be a positive predictor of BP/N 
prescribing, and reversely BP/N prescribing would be a negative predictor of HDOAP. 
These results can be explained by the fact that HDOAP was associated with increased 
risk of OUD,2 which can be treated with BP/N. There was also evidence of discontinuing 
prescription OAs if a person received BP/N treatment for OUD.171  
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Similar to nation-wide trends, an upward trend in BP/N treatment in parallel with 
a downward trend in HDOAP in Kentucky was observed. The increase in BP/N 
prescribing mainly occurred in Appalachia Kentucky, which had a higher rate of HDOAP 
at the start of the observation period and has been an area of the country with particularly 
high rates of opioid-overdose deaths.172 Implementation of DATA 2000 with expanded 
patient limits for waivered providers in Kentucky,77 perceived need among the medical 
community to provide life-saving treatment for OUD, and being an Affordable Care Act 
expansion state,78 may be critical contributors to this increase. Given historically high OA 
prescribing rates in Appalachia, the increase in BP/N treatment may be a first step for 
persons living in this area affected by opioid addiction in order to reduce harms, enter 
into remission, and begin the recovery process. 
Counties with higher heroin-related ED visit rates tended to have lower BP/N 
prescribing rates. It is possible that patients with OUD, who were residing in a county 
where heroin was available, may seek illicit drugs, such as heroin, instead of seeking an 
OUD treatment because heroin has a lower cost and is more easily accessed than 
treament.29 A previous study indicated that difficulties in accessibility to OUD treatment 
may induce a shift to heroin use.160 This result provides important evidence to support a 
special need for improving the availability of buprenorphine, particularly at emergency 
departments where patients present with opioid-related harms such as overdose or 
injection-related infections (e.g. cellulitis), and initiating buprenorphine treatment for the 
underlying disorder at the emergency department is not only logical but also improves 
linkage to ongoing outpatient care of OUD outcomes.173,174 
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This study also revealed that counties with higher HDOAP rates at an earlier time 
point were associated with increased heroin-related ED visit rates later. This finding may 
suggest that a patient addicted to prescription OAs may seek heroin as a substitution if 
the prescription for HDOAP is eliminated or the dose deceased without entry into 
effective OUD treatment. Comprehensive pain management plans that include utilizing 
PDMP records to track history of controlled substance use in order to identify a patient at 
high risk to refer for OUD screening evaluation and timely referral to evidence-based 
OUD treatment has been recommended to prevent this transition to illicit drugs,35 
particularly as the illicit heroin supply now frequently contains highly potent synthetic 
opioids such as fentanyl that are resulting in increasing numbers of overdose deaths.   
While data related to methadone treatment were not available due to strict 
confidentiality requirements governing federal opioid treatment programs that dispense 
methadone, PDMP data are a potential resource to monitor and evaluate the effect of 
OUD treatment using buprenorphine pharmacotherapies. However, the use of PDMP data 
for this purpose has been limited. This study is one of a few studies utilizing PDMP data 
to provide a better understanding of longitudinal effects of buprenorphine treatment at a 
population level on reducing HDOAP. In the context of needing to expand evidence-
based OUD medication treatment, monitoring buprenorphine prescribing plays an 
important role in informing public policy demonstrating its positive impacts despite 
ongoing diversion concerns, guiding interventions and education, and identifying 
potential gaps. This study may stimulate relevant studies or be replicated for other states.  
Although the study’s sample size was not large enough to explore time-varying 
factors and additional pathways associated to the network of the relationship between 
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BP/N prescribing and HDOAP, using the cross-lagged structural equation model for 
multiple repeated measurements of a set of variables enabled us to examine the reciprocal 
relationship between BP/N prescribing and HDOAP, and other related temporal 
directionalities, which have not been reported previously in the literature. Future studies 
on BP/N treatment expansion should take into account this bi-directional association in 
the context of longitudinal panel data and evaluate for public health benefits beyond the 
reduction of HDOAP. 
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Figure 4. 1. Conceptual Framework Depicting a Hypothesized Mechanism for a 
Reciprocal Relationship between High-Dose Opioid Analgesic Prescribing and 
Buprenorphine/Naloxone Prescribing 
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Figure 4. 2. State Rates of High-Dose Opioid Analgesic Prescribing and 
Buprenorphine/Naloxone Prescribing by Quarter, Kentucky 2012 - 2017 
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Figure 4. 3. Quarterly Rates of High-Dose Opioid Analgesic Prescribing and 
Buprenorphine/Naloxone Prescribing by County, Kentucky 2012 and 2017 
 
Abbreviations:  HDOAP = high-dose opioid analgesic prescribing 
  BP/N = buprenorphine/naloxone 
  
Rates of residents with HDOAP per 1,000 residents with opioid analgesic prescriptions
Rates of residents with BP/N prescribing per 1,000 residents with opioid analgesic prescriptions
≤60 >60 and ≤80 >80 and ≤100 >100
≤30 >30 and ≤60 >60 and ≤90 >90
2012 - Quarter 1
2012 - Quarter 1
2017- Quarter 4
2017 - Quarter 4
Appalachian region
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Figure 4. 4. Directions with Coefficient Estimates from the Final Structural Equation Model 
 
Notes: Standard errors are given in parentheses. 
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Table 4. 1. Standardized Coefficients of the Reciprocal Relationship between High-
Dose Opioid Analgesic Prescribing and Buprenorphine/Naloxone Prescribing 
Direction Coefficient 
Estimate 
Standard 
Error 
95% 
Confidence 
Interval 
BP/N prescribing  
HDOAP 
-0.013 0.006 [-0.025; -0.001] 
HDOAP  BP/N 
prescribing 
0.005 0.002 [0.001; 0.009] 
Abbreviations:   HDOAP = high-dose opioid analgesic prescribing;  
BP/N = buprenorphine/naloxone 
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CHAPTER FIVE 
Conclusions 
This dissertation research developed a set of measures for opioid analgesic 
prescribing and co-prescribing based on PDPM data, and computational tools in SAS®.  
Different denominators (i.e., resident population, or number of residents with opioid 
prescriptions) were explored in constructing rates of opioid prescribing at population 
level, as this work showed that the choice of denominator may affect the direction and 
magnitude of temporal changes in opioid analgesic prescribing outcomes.  
This dissertation research also developed a set of proxy measures for prevalence 
of painful conditions justifying opioid analgesic utilization (e.g., rates of emergency 
department visits due to acute traumatic injuries, rates of inpatient hospitalizations and 
emergency department visits involving chronic non-cancer pain, rates of cancer deaths, or 
rates of invasive cancer incidences). Based on literature review, a set of county-level 
covariates were defined and calculated to be used in the adjusted analysis of opioid 
analgesic prescribing changes over time. Examples of such time-varying covariates are 
the availability of opioid use disorder treatment, and availability of heroin in 
communities, access to primary care physicians, and a series of socio-economic and 
demographic measures.  
The dissertation research generated a unique data repository on well defined, 
scientifically-justified data measures, which could be utilized by researchers and public 
health practitioners in Kentucky and the US. Table 5.1 in the Appendix of the dissertation 
provides some of these measures as an example. To access the data repository, visit 
http://www.mc.uky.edu/kiprc/data-and-links/index.html.  
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 The three longitudinal studies included in this dissertation employed advanced 
methodology and statistical analysis to address important public health research 
questions, evaluate trends, patterns, and relationships of opioid analgesic utilization in 
Kentucky, and provide recommendations for public health program and policy actions. 
The results from the study in Chapter Two showed significant downturn in opioid 
prescribing and co-prescribing in Kentucky in the last five years. The changes in the 
number of residents with dispensed opioid analgesic prescriptions per capita over the 
study period were comparable (parallel) across geographical regions and across rural-
urban classification groups. However, the rate of residents with opioid analgesic 
prescriptions in non-metropolitan not adjacent-to-metropolitan counties was significantly 
higher at the beginning of the study and remained significantly higher at the end of the 
study period, regardless of the significant decline over time, and after controlling for 
health conditions justifying opioid  analgesic prescribing. The adjusted models also 
showed that the Kentucky Appalachian region retained a significantly higher rate of 
residents with opioid analgesic prescriptions per 1,000 residents (30% higher than Central 
Kentucky and 19% higher than Kentucky Delta regions). A hot spot of rural counties 
with a significantly higher rate of residents with opioid analgesic prescriptions was 
identified in the center of the mountain Kentucky Appalachian region. This is an 
important finding requiring further investigation as it suggests that the geography and 
travel time/distance to medical centers could be notable barriers for providing non-opioid 
pain treatment alternatives to patients in this region.  
Another important finding of this study was that the acute injuries rates are a risk 
factor for increased opioid analgesic prescribing. Injury prevention efforts and recent 
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Kentucky legislation limiting the initial prescriptions for Schedule II controlled 
substances for acute pain to a three-day supply (with some exceptions) may have a 
positive effect on reducing exposure to opioids. This results also partially motivated the 
investigation on association between high-risk opioid analgesic prescribing and rates of 
acute pain over time in Kentucky, discussed in Chapter Three.  
The study results in Chapter Two also suggested that increased 
buprenorphine/naloxone prescribing could be a significant factor for reducing opioid 
analgesic prescribing rates. These findings motivated the Chapter Four study on the 
possible reciprocal effect of buprenorphine/naloxone prescribing as part of opioid use 
disorder treatment and high dose opioid analgesic prescribing (a measure that could be a 
proxy for opioid analgesic dependence and addiction at population level). 
 The study in Chapter Three indicated a significant, positive association between 
high-risk opioid analgesic prescribing and cancer pain, and no substantial change in the 
association magnitude over time. This finding suggests that recent clinical guidance for 
chronic non-cancer pain has not affected prescribing for cancer pain. This is a positive 
finding given recent concerns about possible under-treatment for cancer pain as 
unintended consequences of interventions for limiting opioid analgesics over-prescribing. 
Chronic non-cancer pain and acute traumatic injury rates were also positively associated 
with high-risk opioid analgesic prescribing, but the association strengths declined over 
time. Given evidence of no advantage of opioid analgesics over non-opioid analgesics for 
chronic non-cancer pain, decreasing high-risk opioid analgesic prescribing practices is 
encouraging. Also, the declining association of acute pain and high-risk opioid analgesic 
prescribing may play a critical role in curtailing inappropriate opioid analgesic 
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prescribing as recent research shows that long-term use of opioid analgesics often 
stemmed from the initial prescribing of opioid analgesics for acute pain. Additional 
research is needed to identify the factors contributing to the decreases (e.g., improved 
prescriber education and clinical practice guidelines for opioid use in chronic non-cancer 
pain treatment, or increased availability of heroin and illicitly manufactured fentanyl). 
In parallel with the decreases in opioid analgesic prescribing, the 
buprenorphine/naloxone prescribing rate increased by more than 5% per quarter in the 
study in Chapter Four. A significant reciprocal relationship between high dose opioid 
analgesic prescribing and buprenorphine/naloxone prescribing was found. A 1/1,000 
higher high dose opioid analgesic prescribing rate in an earlier quarter was significantly 
associated with a 0.01/1,000 increase in the buprenorphine/naloxone prescribing rate in a 
later quarter. Conversely, a one-unit higher buprenorphine/naloxone prescribing rate in an 
earlier quarter was associated with a 0.01/1000 reduction in the high dose opioid 
analgesic prescribing rate in a subsequent quarter. The clinically meaningful effect of 
buprenorphine/naloxone prescribing on reducing opioid analgesic prescribing is 
important evidence supporting expansion of buprenorphine/naloxone treatment, which 
was identified as a realistic and actionable transforming step in a long-term battle against 
the opioid crisis in the US.  
PDMP-based data measures have some limitations. First, PDMP data represent 
dispensed prescriptions rather than actual utilization by patients (i.e. there is no 
information if individuals receiving dispensed prescriptions actually take the dispensed 
medication, and if they take the medications as prescribed). Second, PDMP data in many 
states cannot be linked with health records to identify the diagnosis justifying the 
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prescribing of a dispensed opioid analgesic or to identify health outcomes associated with 
high-risk opioid analgesics utilization at patient level. Third, patient-level information 
that may affect prescriber practices or patient’s drug-seeking behavior, such as education, 
occupation, income, health insurance coverage, or comorbidity conditions, are not 
collected from PDMPs. In addition, the heterogeneity of PDMP features should be 
considered in multi-state analyses on opioid prescribing trends. 
Although individual-level inferences cannot be made from the studies, and using 
proxy variables to measure medical needs for pain treatment, availability of medication 
treatment for opioid use disorder, and availability of heroin may introduce 
misclassification bias or increase residual confounding into the studies, the findings 
advanced the understanding of the epidemiology of opioid use and misuse in Kentucky, 
and identified actionable risk and protective factors that can inform policy, education, and 
drug overdose prevention interventions.  
Despite the transition from prescription opioids to heroin and illicitly 
manufactured fentanyl as leading drugs in opioid-related overdose deaths, PDMPs play 
an important role in preventing medically unnecessary exposure to prescription opioid 
analgesics that may lead to developing opioid dependence, opioid use disorders, 
transition to illicit opioid drug use, and drug overdose.  
The developed operational definition inventory and computational tools can 
facilitate establishing population-level, PDMP-based consensus measures for opioid 
analgesic utilization and uniform operationalization by researchers and agencies. The 
studies can stimulate further utilization of PDMP data in Kentucky and in other states for 
enhancing public health surveillance and epidemiological analysis, to support policy 
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development and evaluation, inform targeted prescriber and patient education on 
responsible opioid prescribing and co-prescribing, and support state and local opioid 
overdose prevention program planning and decision making.  
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APPENDIX 
Table 1. 1.  PDMP-Based Measures and Metrics by State 
State Name of PDMP Operational 
Year 
Tracking Measures and Metrics 
Alabama Alabama PDMP, 
Alabama Department 
of Public Health 
2006  NA 
Alaska Alaska PDMP, 
Alaska Board of 
Pharmacy, Division 
of Corporations, 
Business and 
Professional 
Licensing 
2011  NA 
Arizona Arizona Controlled 
Substances 
Prescription 
Monitoring Program, 
Arizona State Board 
of Pharmacy 
2008  NA 
Arkansas Arkansas PDMP, 
Arkansas Department 
of Health 
2013  NA 
California Controlled Substance 
Utilization Review 
and Evaluation 
System (CURES), 
California 
Department of Justice 
1939 • Total number of prescriptions for opioid drugs in patient's 
locale, prescriber's locale and dispenser's locale 
• Total number of unique patients prescribed opioids in patient's 
locale, prescriber's locale, and dispenser's locale 
• Number of opioid pills prescribed in patient's locale 
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Table 1.1 Continued 
State Name of PDMP Operational 
Year 
Tracking Measures and Metrics 
   • Number of opioid pill prescription fills, including refills, in 
patient's locale 
• Mean number of opioid pills per prescription in patient's locale 
• Number of patients prescribed both opioids and 
benzodiazepine in prescriber's local 
• Total MME prescribed in prescriber's locale 
• Total number of prescriptions all schedule II drugs in 
prescriber's locale 
• Total number patients receiving schedule II, III and IV drug 
prescriptions in patient's locale (patient receives prescriptions 
from all three schedules) 
• Number of pills prescribed for schedules II, III and IV drugs in 
prescriber's locale (patient receives pills from all three 
schedules) 
• Number of prescriptions for schedules II, III and IV drugs in 
prescriber's locale (patient receives prescriptions from all three 
schedules) 
• Mean number of pills per prescription for schedules II, III and 
IV drugs in prescriber's locale (patient receives pills from all 
three schedules) 
• Number of pills prescribed for schedule II drugs in prescriber's 
locale 
• Number of prescriptions for schedule II drugs in prescriber's 
locale 
• Mean number of pills per prescription for schedule ii drugs in 
prescriber's locale 
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Table 1.1 Continued 
State Name of PDMP Operational 
Year 
Tracking Measures and Metrics 
   • Number of patients who obtained six prescriptions from six or 
more dispensers during prior six months in patients' locale 
• Number of patients with same prescription drug from 3 or 
more prescribers in patients' locale 
• Numbers of prescribers prescribing opioids and 
benzodiazepines concurrently to a patient in prescriber's locale 
• Number of patients currently prescribed more than 100 MME 
per day in prescriber's locale 
• Number of patients who are currently prescribed more than 40 
milligrams methadone daily in prescriber's locale 
• Number of prescriber registrants in prescriber's locale and 
dispenser's locale 
• Number of cures inquiries by prescribers in prescriber's and 
dispenser's locale 
Colorado Colorado Electronic 
PDMP, Colorado 
State Board of 
Pharmacy 
2007 • Prescriptions dispensed 
• Patients receiving prescriptions 
• Queries performed 
Connecticut Connecticut 
Prescription 
Monitoring and 
Reporting System, 
Department of 
Consumer Protection 
2008 • Controlled substance prescriptions/year 
• Prescriptions per quarter 
• Prescriptions by drug schedule 
• Controlled substance prescription rate 
• New vs. refill prescriptions 
• Percentage prescriptions >90 MME vs. all 
• Opioid vs. non-opioid prescriptions 
• Opioid prescriptions per year 
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Table 1.1 Continued 
State Name of PDMP Operational 
Year 
Tracking Measures and Metrics 
   • Opioid prescription rate by patient residence 
• Opioid agonist prescription rates by patient residence 
• Benzodiazepine prescriptions per year  
• Most prescribed controlled substances 
• Licensed dispensers reporting to the CPMRS 
Delaware Delaware PDMP, 
Division of 
Professional 
Regulation, Office of 
Controlled 
Substances 
2012  NA 
District of 
Columbia 
DC PDMP, 
Pharmaceutical 
Control Division  
2016  NA 
Florida Electronic-Florida 
Online Reporting of 
Controlled Substance 
Evaluation Program 
(E-FORCSE), 
Department of Health 
2011 • Percentage of the surveyed health care practitioners who 
considered E-FORCSE a “useful/somewhat useful” tool to 
identify “doctor shopping”  
• Number of patients receiving concurrent prescriptions of an 
opioid, alprazolam and carisoprodol in a month 
• Prescription rates by drug class, sex, and age group  
• Prescriptions per 1,000 county residents for all controlled 
substance prescriptions in schedules II - IV, opioids, 
stimulants, and benzodiazepines 
• Number and percentage of unique patients with controlled 
substance prescriptions paid for by Medicaid and cash 
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Table 1.1 Continued 
State Name of PDMP Operational 
Year 
Tracking Measures and Metrics 
   • Topics that health care practitioners communicate more with 
others as a result of using E-FORCSE 
• Number of individuals obtaining controlled substance 
prescriptions in schedules II-IV from 5/10 or more prescribers 
and 5/10 or more dispensers within a 90-day period 
• Proactive notification reports by practice type 
• Opioid naïve patient opioid use characteristics  
• The number of unique Florida residents and average number of 
prescriptions per person by controlled substance schedule 
• The number of prescriptions, unique patients and prescribers 
by report year and percentage of change 
• The number of prescriptions and percentage of total 
prescriptions of the top 10 most commonly dispensed 
controlled substances to Florida residents 
• Health care practitioner registration and utilization by license 
type, report year and percentage change 
• Investigative agency registration and utilization by agency type  
• Proactive notification reports by type, percent change 
Georgia Georgia PMP, 
Georgia Department 
of Public Health 
2013  NA 
Guam Guam PDMP, 
Department of Public 
Health and Social 
Services 
2013  NA 
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Table 1.1 Continued 
State Name of PDMP Operational 
Year 
Tracking Measures and Metrics 
Hawaii Hawaii Electronic 
Prescription 
Accountability 
System, Narcotics 
Enforcement 
Division 
1943  NA 
Idaho Idaho PMP, Board of 
Pharmacy 
1967  NA 
Illinois Illinois PMP: 
Prescription 
Information Library, 
Department of 
Human Services 
1968 •  >90 MME rate 
• High risk patient populations 
• Average day's supply 
• Total patients 
• Total prescriptions 
• Naloxone  distribution locations  
• Number of controlled substance prescribers by county 
• By-county prescribers accessing ILPMP in the last six months 
• Number of prescribers used by county residents 
• Patients on holy trinity medication per 100,000 population 
Indiana Indiana Scheduled 
Prescription 
Electronic Collection 
and Tracking, Indiana 
Professional 
Licensing Agency 
1998  NA 
Iowa Iowa PMP, Iowa 
Board of Pharmacy 
2009  NA 
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Table 1.1 Continued 
State Name of PDMP Operational 
Year 
Tracking Measures and Metrics 
Kansas Kansas Tracking and 
Reporting of 
Controlled 
Substances,  Kansas 
Board of Pharmacy 
2011  NA 
Kentucky Kentucky All 
Schedule Prescription 
Electronic Reporting 
(KASPER), 
Kentucky Cabinet for 
Health and Family 
Services 
1999 • Number of KASPER reports requested 
• KASPER usage 
• Number of prescription filled and doses dispensed 
• A breakdown of drug schedule dispensing by county 
• A breakdown of drug schedule dispensing by age and gender 
• Average prescriptions, doses, and patient MME for each 
practitioner by grouped area of work 
• Rate of opioid prescription dispensing by age and gender 
• Number and rate of medication-assisted treatment prescriptions 
filled by county 
• Number and rate of medication-assisted treatment prescriptions 
filled by age and gender 
• Number of patients with daily dose of ≥100 MME 
• Number of patients with concurrent opioid and benzodiazepine 
prescriptions 
Louisiana Louisiana PMP, 
Louisiana Board of 
Pharmacy 
2008 • Number of prescriptions 
• Transactions reported 
• New prescribers registered 
• Total prescribers registered 
• New pharmacists registered 
 
 
 
 
92 
Table 1.1 Continued 
State Name of PDMP Operational 
Year 
Tracking Measures and Metrics 
   • Total pharmacists registered 
• New pharmacist delegates registered 
• Total pharmacist delegates registered 
• Searches performed by users 
• Average queries per day 
• Number of prescriptions reported to the Louisiana PMP 
• PMP searches by prescribers and pharmacists 
Maine Maine PMP, Maine 
Department of Health 
and Human Services, 
Office of Substance 
Abuse 
2004  NA 
Maryland Maryland PDMP, 
Department of Health 
and Mental Hygiene, 
Alcohol and Drug 
Abuse 
Administration 
2013  NA 
Massachusetts Massachusetts PMP, 
Department of Public 
Health 
1994 • Total schedule II opioid prescriptions 
• Total number of schedule II opioid solid dosage units 
• Individuals receiving schedule II opioid prescription 
• Percentage of individuals receiving schedule II opioid 
prescription (of total population) 
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Table 1.1 Continued 
State Name of PDMP Operational 
Year 
Tracking Measures and Metrics 
   • Number and rate of individuals with activity of concern 
(Schedule II opioid controlled substance prescriptions from 
different prescribers and having those prescriptions dispensed 
at different pharmacies) 
Michigan Michigan Automated 
Prescription System, 
Michigan Department 
of Licensing and 
Regulatory Affairs, 
Bureau of 
Professional 
Licensing 
1989 • Total prescriptions 
• Total prescriptions quantity 
• Total prescriptions days supply 
• Total prescriptions opioid MMEs (excluding buprenorphine) 
• Prescriptions by drug schedule vs. average days supply 
• Total prescriptions by drug schedule for each month 
• Percentage prescriptions greater than 90 MMEs 
• Percentage new prescriptions vs. refill prescriptions 
• Percentage opioid prescriptions vs. non-opioid prescriptions 
Minnesota Minnesota  PMP, 
Minnesota  Board  of 
Pharmacy 
2010 • Recipients filled prescriptions from multiple different 
prescribers  
• Multiple prescriber and dispenser episodes by recipient count 
• Prescription count and average of federally scheduled  
• Prescriptions dispensed per population 
• Crude rate of opioids dispensed per 1,000 residents 
• Partial opiate agonists reported as dispensed 
• Stimulants reported as dispensed 
• Sedatives reported as dispensed 
• Benzodiazepines reported as dispensed 
• Percentage have requested and obtained access to the PMP 
• Database utilization 
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Table 1.1 Continued 
State Name of PDMP Operational 
Year 
Tracking Measures and Metrics 
Mississippi Mississippi PMP, 
Mississippi Board of 
Pharmacy 
2005 • Total opioid prescriptions 
• Total number of naloxone administrations 
• Patients with opioid  prescriptions 
• People with at least one opioid prescription 
• Number of prescriptions filled 
• Average number of prescriptions filled per patient 
• Benzodiazepine prescriptions: similar indicators 
• Per capita patients with benzodiazepine prescriptions 
• Concurrent opioid and benzodiazepine prescriptions 
• Per capita patients with concurrent opioid and benzodiazepine 
prescriptions 
• Average daily MME per opioid fill 
• Opioid and benzodiazepine prescription fills on the same day, 
relative to days patient had one or more opioid prescriptions 
• Length of time patients received opioid prescriptions 
Montana Montana Prescription 
Drug Registry, 
Montana Board of 
Pharmacy 
2012  NA 
MO-St Louis 
City 
St Louis County 
PDMP, St Louis 
County Department 
of Public Health 
2017  NA 
Nebraska Nebraska PDMP, 
Nebraska Health 
Information Initiative 
2011  NA 
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Table 1.1 Continued 
State Name of PDMP Operational 
Year 
Tracking Measures and Metrics 
Nevada Nevada Prescription 
Controlled Substance 
Abuse Prevention 
Task Force, Board of 
Pharmacy 
1997  NA 
New 
Hampshire 
New Hampshire 
PDMP, New 
Hampshire Board of 
Pharmacy 
2014  NA 
New Jersey New Jersey 
Prescription 
Monitoring and 
Reporting System, 
Division of 
Consumer Affairs, 
Department of Law 
and Public Safety 
2011  NA 
New Mexico New Mexico 
Controlled Substance 
Prescription 
Monitoring Program, 
New Mexico State 
Board of Pharmacy 
2005  NA 
New York New York Official 
Prescription Program, 
New York State 
Department of Health 
1973 • Opioid analgesics prescription rate per 1,000 population 
• Crude rate of patients prescribed opioid analgesics from five or 
more prescribers and dispensed at five or more pharmacies per 
100,000 population 
 
 
 
 
96 
Table 1.1 Continued 
State Name of PDMP Operational 
Year 
Tracking Measures and Metrics 
   • Buprenorphine prescribing for substance use disorder, rate per 
1,000 population 
• Benzodiazepine prescription rate per 1,000 population 
North Carolina North Carolina 
Controlled 
Substances Reporting 
System, North 
Carolina Department 
of Health and Human 
Services, Division of 
Mental Health, 
Developmental 
Disabilities and 
Substance Abuse 
Services 
2007  NA 
North Dakota North Dakota PDMP, 
North Dakota Board 
of Pharmacy 
2007 • Prescription count 
• Prescription per person 
• Total dosage units 
• Units per person 
Ohio Ohio Automated Rx 
Reporting System, 
Ohio State Board of 
Pharmacy 
2006  NA 
Oklahoma Oklahoma PMP, 
Oklahoma Bureau of 
Narcotics 
1991  NA 
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Table 1.1 Continued 
State Name of PDMP Operational 
Year 
Tracking Measures and Metrics 
Oregon Oregon PDMP, 
Oregon Public Health 
Division, Department 
of Human Services 
2011 • PDMP query statistics by user group 
• Top prescriptions  
• Prescriptions for buprenorphine/ naloxone  
• 4+ prescriber and 4+ pharmacy individuals per 1,000 residents 
• >50 MED individuals per 1,000 residents from a single fill 
• >50 MED individuals per 1,000 residents from any fill 
• >90 MED individuals per 1,000 residents from a single fill 
• >90 MED individuals per 1,000 residents from any fill 
• >120 MED individuals per 1,000 residents from a single fill 
• >120 MED individuals per 1,000 residents from any fill 
• Overlapping opioid /benzodiazepine individuals per 1,000 
residents 
• Percent of patients going from acute to chronic opioids 
Pennsylvania Pennsylvania 
PDMP, Pennsylvania 
Department of Health 
1973 • Number/rate per 1,000 population of individuals seeing 5+ 
prescribers and 5+ dispensers 
• Number/rate per 1,000 population of individuals with an 
average daily MME >50, >90 or >120 
• Number/rate per 1,000 population of individuals with 
overlapping opioid/benzodiazepine prescriptions per 1,000 
population 
Puerto Rico Puerto Rico PDMP, 
Mental Health and 
Anti-Addiction 
Services 
Administration 
2018  NA 
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Table 1.1 Continued 
State Name of PDMP Operational 
Year 
Tracking Measures and Metrics 
Rhode Island Rhode Island PMP, 
Department of 
Health, Board of 
Pharmacy 
1979  NA 
South Carolina South Carolina 
Reporting and 
Identification 
Prescription Tracking 
System, South 
Carolina Department 
of Health and 
Environmental 
Control 
2008  NA 
South Dakota South Dakota PDMP, 
South Dakota Board 
of Pharmacy 
2011  NA 
Tennessee Controlled Substance 
Monitoring Database 
(CSMD), Tennessee 
Department of 
Health; Tennessee 
Board of Pharmacy 
2006 • MME dispensed 
• MME dispensed by top 50 prescribers  
• Number of pain clinics  
• Number of potential doctor shoppers 
• Number of all opioid prescriptions 
• Patients receiving >120 MME/day 
• Searches of CSMD 
• Number of prescriptions for stimulants 
• Number of prescriptions for buprenorphine 
• Prescriptions without CSMD evaluation  
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Table 1.1 Continued 
State Name of PDMP Operational 
Year 
Tracking Measures and Metrics 
Texas Texas Prescription 
Program, Texas State 
Board of Pharmacy 
1982 • Total number of controlled substance prescriptions dispensed 
• Number of patients potentially doctor-shopping 
Utah Utah Controlled 
Substance Database 
Program, Utah 
Division of 
Occupational and 
Professional 
Licensing, Utah 
Department of 
Commerce 
1996  NA 
Vermont Vermont Prescription 
Monitoring System, 
Department of Health 
2009 • Total number of prescriptions 
• Total number of recipients 
• Percentage of residents having opioid prescriptions 
• Average daily MME per prescription by quarter 
• Total MME dispensed by quarter 
• Percent of population receiving at least one opioid  
• Analgesic prescription by quarter 
• Average days’ supply and MME for opioid analgesics 
• Proportion of opioid analgesic prescriptions in MME 
categories 
• Rate of prescriptions per 100 residents by drug class 
• Number of prescriptions in each drug class 
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Table 1.1 Continued 
State Name of PDMP Operational 
Year 
Tracking Measures and Metrics 
Virginia Virginia PMP, 
Virginia Department 
of Health Professions 
2003 • Number of residents receiving opioid prescriptions 
• Number of opioid prescription days for residents 
• Rate of multiple provider episodes for prescription opioids 
(five or more prescribers and five or more pharmacies in a six 
month period) 
• Percentage of days with overlapping opioid and opioid-
benzodiazepine prescriptions 
• Doses dispensed by drug type 
• Database utilization 
Washington Washington 
Prescription 
Review, Washington 
State Department of 
Health 
2011 • Patients with any opioid prescription 
• Patients with chronic opioid prescriptions 
• Patients with high dose opioid prescriptions 
• Patients with concurrent opioid and sedative prescriptions 
• Patients with new opioid prescriptions by day’s supply 
• Patients with new chronic opioid prescriptions 
• PDMP queries and utilizations 
• Type of substance dispensed 
West Virginia West Virginia 
PDMP, West 
Virginia Board of 
Pharmacy 
1995  NA 
Wisconsin Wisconsin PDMP, 
Wisconsin Controlled 
Substances Board 
2013  NA 
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Table 1.1 Continued 
State Name of PDMP Operational 
Year 
Tracking Measures and Metrics 
Wyoming Wyoming 
PDMP, Board of 
Pharmacy 
2004  NA 
Abbreviations:  MED = Morphine Equivalent Dose  
MME = Morphine Milligram Equivalents  
NA = Not Available 
PDMP = Prescription Drug Monitoring Program 
PMP = Prescription Monitoring Program 
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Table 5. 1. PDMP-Based Measures for Opioid Prescribing by County and by Year, Kentucky 2012 – 2017 
County Year OAP HDOAP LTOAP LTHDOAP CPOAB CPOA LAOAP BPN 
Adair 2012 4509 202 528 74 997 606 20 92 
Adair 2013 4470 165 618 66 953 556 14 119 
Adair 2014 4516 147 649 57 937 582 20 181 
Adair 2015 4598 155 702 58 986 549 12 228 
Adair 2016 4464 130 639 51 835 404 11 232 
Adair 2017 4023 123 651 47 681 376 7 266 
Allen 2012 5401 330 837 126 1057 808 33 26 
Allen 2013 4858 278 790 111 944 629 22 38 
Allen 2014 4773 269 728 111 732 591 15 50 
Allen 2015 4880 244 781 107 654 501 12 52 
Allen 2016 4811 212 800 93 625 476 15 70 
Allen 2017 4476 205 766 77 474 459 12 94 
Anderson 2012 5972 335 759 129 871 732 21 85 
Anderson 2013 5696 298 737 110 748 592 34 129 
Anderson 2014 5389 252 609 85 592 509 31 182 
Anderson 2015 5587 270 636 88 593 534 33 189 
Anderson 2016 5678 264 708 94 611 524 31 187 
Anderson 2017 5099 222 648 83 527 448 24 224 
Ballard 2012 1916 123 289 32 368 266 6 12 
Ballard 2013 1740 92 250 20 319 205 6 13 
Ballard 2014 1777 92 285 24 325 219 6 14 
Ballard 2015 1783 89 313 22 306 231 2 17 
Ballard 2016 1715 94 294 19 302 208 1 22 
Ballard 2017 1605 83 312 23 268 192 3 21 
Barren 2012 11017 509 1249 163 1786 1447 58 98 
Barren 2013 10351 411 1230 136 1584 1089 31 120 
Barren 2014 10524 434 1245 137 1441 1244 24 153 
Barren 2015 10473 397 1282 150 1314 984 27 185 
Barren 2016 10441 360 1354 147 1260 930 14 236 
Barren 2017 9889 336 1360 134 1107 843 21 287 
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County Year OAP HDOAP LTOAP LTHDOAP CPOAB CPOA LAOAP BPN 
Bath 2012 3280 350 538 139 534 660 32 102 
Bath 2013 3098 225 489 95 384 447 23 111 
Bath 2014 3239 225 475 71 354 438 24 169 
Bath 2015 3163 181 473 63 358 392 15 208 
Bath 2016 3101 148 452 58 322 342 9 268 
Bath 2017 2805 152 407 54 270 315 11 297 
Bell 2012 10770 442 3077 149 3467 2430 41 368 
Bell 2013 10058 355 2763 130 3252 1856 31 468 
Bell 2014 9969 369 2837 121 3287 2357 25 637 
Bell 2015 9878 338 2818 112 3374 1830 25 562 
Bell 2016 9372 250 2681 77 3067 1422 20 536 
Bell 2017 8498 205 2407 68 2503 1102 15 606 
Boone 2012 26840 1753 2812 728 3385 2696 121 265 
Boone 2013 26000 1448 2573 606 2830 2146 118 277 
Boone 2014 25809 1515 2498 628 2594 2718 128 288 
Boone 2015 25920 1213 2418 552 2532 1779 120 355 
Boone 2016 25229 1134 2360 507 2285 1650 107 382 
Boone 2017 23634 1042 2286 450 2065 1525 81 414 
Bourbon 2012 5356 349 586 127 641 822 25 147 
Bourbon 2013 4713 274 500 105 527 637 23 181 
Bourbon 2014 4888 247 570 96 587 614 31 234 
Bourbon 2015 5084 238 619 85 584 592 21 332 
Bourbon 2016 5131 196 550 65 518 467 17 368 
Bourbon 2017 4658 170 486 51 417 420 16 411 
Boyd 2012 14180 905 1653 314 2174 1813 60 364 
Boyd 2013 12871 771 1560 298 1838 1369 42 538 
Boyd 2014 12298 687 1303 262 1624 1132 38 737 
Boyd 2015 12112 520 1108 180 1472 985 40 801 
Boyd 2016 11525 441 1007 157 1269 870 29 894 
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County Year OAP HDOAP LTOAP LTHDOAP CPOAB CPOA LAOAP BPN 
Boyd 2017 10398 355 953 116 1159 736 28 945 
Boyle 2012 7018 476 1240 213 1443 1119 33 136 
Boyle 2013 6719 348 1187 125 1334 889 38 148 
Boyle 2014 6854 292 1129 110 1292 805 51 188 
Boyle 2015 6787 283 1126 103 1176 766 33 224 
Boyle 2016 6577 262 1036 78 1048 647 27 230 
Boyle 2017 6007 242 933 78 875 567 27 274 
Bracken 2012 2302 140 259 49 333 310 14 29 
Bracken 2013 2170 122 260 54 323 236 11 34 
Bracken 2014 2370 118 246 39 337 250 15 34 
Bracken 2015 2324 106 229 33 325 224 12 47 
Bracken 2016 2152 91 212 30 286 200 11 42 
Bracken 2017 2022 80 224 30 271 181 15 57 
Breathitt 2012 5157 289 1216 134 1518 1000 12 203 
Breathitt 2013 4737 231 1211 120 1330 780 14 262 
Breathitt 2014 4724 218 1129 107 1099 757 13 347 
Breathitt 2015 4560 205 1067 87 1049 624 7 367 
Breathitt 2016 4114 173 1020 80 888 496 5 440 
Breathitt 2017 3831 141 953 74 740 399 5 485 
Breckinridge 2012 4533 295 596 99 798 595 13 18 
Breckinridge 2013 4336 244 575 103 669 479 20 23 
Breckinridge 2014 4653 276 631 89 687 632 18 21 
Breckinridge 2015 4521 234 621 99 625 462 18 32 
Breckinridge 2016 4476 189 597 80 613 436 14 33 
Breckinridge 2017 4227 192 613 64 503 373 7 36 
Bullitt 2012 16198 1131 2126 434 2275 2045 44 138 
Bullitt 2013 15061 911 2003 359 1901 1578 56 158 
Bullitt 2014 15152 1026 1986 329 1823 2287 32 212 
Bullitt 2015 15386 846 1986 301 1793 1348 38 271 
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County Year OAP HDOAP LTOAP LTHDOAP CPOAB CPOA LAOAP BPN 
Bullitt 2016 15106 783 2004 288 1666 1269 52 310 
Bullitt 2017 14277 695 2004 274 1513 1057 32 346 
Butler 2012 3375 213 622 72 704 605 7 14 
Butler 2013 2980 161 508 56 516 363 9 20 
Butler 2014 3025 226 496 74 424 754 5 22 
Butler 2015 3202 137 540 50 411 334 4 24 
Butler 2016 3104 144 597 49 395 322 3 27 
Butler 2017 2930 128 521 38 314 285 3 39 
Caldwell 2012 3680 241 533 66 581 552 12 35 
Caldwell 2013 3390 173 516 62 523 378 9 46 
Caldwell 2014 3334 167 486 56 479 395 10 45 
Caldwell 2015 3402 156 514 47 482 311 15 56 
Caldwell 2016 3351 152 512 52 499 303 5 71 
Caldwell 2017 3071 147 504 44 438 281 16 80 
Calloway 2012 8563 539 1068 151 1404 1233 40 49 
Calloway 2013 7824 483 1041 149 1263 911 26 57 
Calloway 2014 7940 498 1036 141 1246 1125 45 54 
Calloway 2015 8161 454 1059 140 1286 844 29 65 
Calloway 2016 8046 449 1145 143 1297 837 30 69 
Calloway 2017 7452 376 1102 118 1198 772 24 102 
Campbell 2012 20102 1382 2416 576 2663 2154 96 217 
Campbell 2013 19125 1163 2152 528 2281 1711 114 229 
Campbell 2014 18792 1112 2058 479 2090 2029 97 251 
Campbell 2015 18694 926 1984 407 2023 1383 69 319 
Campbell 2016 17544 857 1957 385 1871 1295 69 353 
Campbell 2017 16174 730 1883 316 1607 1136 62 400 
Carlisle 2012 1498 86 224 18 278 198 2 10 
Carlisle 2013 1366 59 215 10 235 142 4 13 
Carlisle 2014 1337 80 206 15 233 183 7 12 
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County Year OAP HDOAP LTOAP LTHDOAP CPOAB CPOA LAOAP BPN 
Carlisle 2015 1366 70 225 13 242 154 4 15 
Carlisle 2016 1309 56 234 17 236 131 5 10 
Carlisle 2017 1218 53 232 12 209 156 5 19 
Carroll 2012 3587 262 419 92 509 576 10 83 
Carroll 2013 3367 204 433 77 434 384 24 76 
Carroll 2014 3466 229 522 80 435 438 12 94 
Carroll 2015 3511 203 477 68 415 360 10 115 
Carroll 2016 3334 148 492 58 363 279 8 101 
Carroll 2017 2997 94 446 34 332 226 8 100 
Carter 2012 7052 460 818 179 1064 918 21 251 
Carter 2013 6300 339 742 139 866 721 31 332 
Carter 2014 6168 333 678 127 800 669 23 454 
Carter 2015 6018 287 569 91 708 538 20 513 
Carter 2016 5922 225 569 94 631 451 12 552 
Carter 2017 5322 205 535 64 552 403 13 596 
Casey 2012 3875 220 666 79 947 670 17 87 
Casey 2013 3652 164 669 73 879 554 15 89 
Casey 2014 3796 155 664 65 911 572 22 119 
Casey 2015 3799 150 685 67 905 497 13 149 
Casey 2016 3708 114 623 50 792 381 9 162 
Casey 2017 3184 96 524 33 560 289 5 190 
Christian 2012 13797 626 1443 136 1613 1744 52 98 
Christian 2013 12751 438 1390 114 1492 1148 41 121 
Christian 2014 12323 490 1298 135 1312 1343 52 127 
Christian 2015 12289 481 1343 132 1254 1020 26 117 
Christian 2016 12051 451 1405 144 1217 1073 47 153 
Christian 2017 11367 441 1445 137 1132 1039 30 179 
Clark 2012 9570 904 1520 323 1604 1653 55 169 
Clark 2013 8492 644 1345 258 1142 1173 59 311 
 
 
 
107 
Table 5.1 Continued 
County Year OAP HDOAP LTOAP LTHDOAP CPOAB CPOA LAOAP BPN 
Clark 2014 8649 623 1212 221 1017 1270 52 436 
Clark 2015 8681 535 1265 221 968 1154 57 525 
Clark 2016 8373 497 1192 190 908 1017 46 578 
Clark 2017 7882 413 1095 150 747 829 35 643 
Clay 2012 7676 902 2103 287 2400 2399 21 373 
Clay 2013 6771 467 2005 156 1810 1533 34 496 
Clay 2014 7174 364 2124 154 1851 1344 60 537 
Clay 2015 7015 320 2184 153 1775 1073 21 583 
Clay 2016 6504 299 2146 147 1714 918 17 565 
Clay 2017 6114 232 2000 120 1376 717 17 660 
Clinton 2012 3208 277 746 82 1079 781 13 26 
Clinton 2013 3281 242 827 95 1067 665 12 34 
Clinton 2014 3319 274 824 88 1071 639 16 42 
Clinton 2015 3150 195 688 73 970 443 9 63 
Clinton 2016 2879 155 651 60 686 367 4 62 
Clinton 2017 2650 104 566 35 556 233 3 85 
Crittenden 2012 2598 180 583 63 601 460 5 10 
Crittenden 2013 2306 152 523 54 485 318 11 15 
Crittenden 2014 2380 262 544 70 458 684 5 22 
Crittenden 2015 2439 190 551 67 530 359 7 28 
Crittenden 2016 2443 180 569 62 519 304 6 32 
Crittenden 2017 2222 132 510 44 415 249 7 48 
Cumberland 2012 2491 120 285 39 582 271 8 38 
Cumberland 2013 2386 171 312 39 608 697 11 39 
Cumberland 2014 2303 112 330 38 597 299 6 47 
Cumberland 2015 2213 113 328 31 585 296 5 74 
Cumberland 2016 2140 107 308 34 500 228 4 73 
Cumberland 2017 1908 86 336 32 372 176 5 90 
Daviess 2012 25605 1397 2971 435 3816 3076 126 101 
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County Year OAP HDOAP LTOAP LTHDOAP CPOAB CPOA LAOAP BPN 
Daviess 2013 23874 1236 2761 378 3346 2411 110 114 
Daviess 2014 24477 1324 2852 373 3488 2931 109 135 
Daviess 2015 24484 1161 3065 345 3363 2279 102 161 
Daviess 2016 24002 1062 2993 291 3188 2026 108 204 
Daviess 2017 22759 851 2723 239 2716 1672 111 229 
Edmonson 2012 2635 165 373 59 501 481 7 28 
Edmonson 2013 2275 130 374 53 416 323 4 29 
Edmonson 2014 2354 139 409 55 418 380 6 30 
Edmonson 2015 2420 126 412 48 375 312 5 26 
Edmonson 2016 2378 116 431 50 354 258 3 25 
Edmonson 2017 2247 111 403 46 296 228 4 33 
Elliott 2012 1298 98 185 37 241 223 2 42 
Elliott 2013 1130 78 174 27 209 162 4 50 
Elliott 2014 1156 67 143 23 201 147 7 86 
Elliott 2015 1157 68 164 30 188 134 3 103 
Elliott 2016 1070 58 168 28 175 118 5 110 
Elliott 2017 989 42 131 16 132 89 2 129 
Estill 2012 5058 526 876 182 978 1410 23 191 
Estill 2013 4606 366 868 151 838 759 28 250 
Estill 2014 4826 308 924 121 905 744 33 345 
Estill 2015 4706 257 830 101 773 598 14 386 
Estill 2016 4684 208 827 82 687 584 11 398 
Estill 2017 4334 180 784 60 613 523 5 457 
Fayette 2012 60045 3285 5683 1144 6219 7285 453 868 
Fayette 2013 55649 2728 5248 977 5341 5528 471 1120 
Fayette 2014 56570 2848 4976 871 5070 6329 475 1343 
Fayette 2015 57854 2548 4937 766 4812 5230 443 1588 
Fayette 2016 56521 2204 4720 692 4548 4747 399 1697 
Fayette 2017 52298 1968 4454 580 3818 4128 321 1997 
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County Year OAP HDOAP LTOAP LTHDOAP CPOAB CPOA LAOAP BPN 
Fleming 2012 3455 238 412 95 613 544 15 67 
Fleming 2013 3245 174 415 75 573 402 25 85 
Fleming 2014 3432 174 396 68 516 395 23 78 
Fleming 2015 3654 166 444 66 524 397 12 85 
Fleming 2016 3477 151 424 57 472 353 12 97 
Fleming 2017 3181 128 420 49 381 306 6 130 
Floyd 2012 15114 1201 4309 495 5185 3787 32 512 
Floyd 2013 13812 798 3819 287 4070 2637 43 603 
Floyd 2014 13864 611 3666 245 3506 2264 49 865 
Floyd 2015 13857 621 3519 267 3237 1838 52 1021 
Floyd 2016 13268 580 3233 266 2934 1666 36 1200 
Floyd 2017 12235 487 3137 229 2602 1444 40 1509 
Franklin 2012 13456 663 1534 253 1590 1575 66 179 
Franklin 2013 12521 538 1400 205 1364 1148 48 242 
Franklin 2014 12254 538 1323 186 1261 1329 64 317 
Franklin 2015 12382 475 1337 176 1176 1018 49 377 
Franklin 2016 11665 420 1373 157 1105 955 53 441 
Franklin 2017 10571 388 1344 141 1010 807 46 529 
Fulton 2012 2027 85 273 14 361 242 5 16 
Fulton 2013 1694 57 220 8 306 187 6 13 
Fulton 2014 1757 63 206 8 277 183 5 8 
Fulton 2015 1815 50 265 13 256 158 8 12 
Fulton 2016 1812 63 276 13 261 173 4 16 
Fulton 2017 1716 54 289 8 243 134 5 20 
Gallatin 2012 2128 208 304 73 388 312 15 26 
Gallatin 2013 1994 153 287 67 288 251 6 24 
Gallatin 2014 2030 183 342 75 284 300 9 28 
Gallatin 2015 2009 153 329 59 269 238 10 35 
Gallatin 2016 1896 132 320 57 218 182 3 49 
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County Year OAP HDOAP LTOAP LTHDOAP CPOAB CPOA LAOAP BPN 
Gallatin 2017 1815 101 292 51 182 142 4 56 
Garrard 2012 4225 458 753 203 815 874 34 87 
Garrard 2013 3925 362 698 168 687 597 33 126 
Garrard 2014 3953 334 685 144 665 631 29 151 
Garrard 2015 4083 311 682 135 662 516 23 188 
Garrard 2016 4023 268 655 110 601 461 14 192 
Garrard 2017 3824 212 619 73 474 445 19 209 
Grant 2012 7999 724 1236 311 1587 1132 30 85 
Grant 2013 7232 574 1065 271 1118 806 32 92 
Grant 2014 7217 505 985 226 1021 787 36 100 
Grant 2015 7225 427 979 202 901 617 18 121 
Grant 2016 7097 424 964 183 746 548 17 144 
Grant 2017 6485 354 937 156 645 508 17 201 
Graves 2012 10744 532 1484 132 1822 1281 39 38 
Graves 2013 9683 445 1377 127 1584 983 45 47 
Graves 2014 9691 515 1393 120 1593 1262 45 67 
Graves 2015 9932 488 1491 130 1662 1012 33 107 
Graves 2016 9908 443 1523 126 1573 965 26 121 
Graves 2017 9246 423 1548 99 1414 878 27 213 
Grayson 2012 8348 565 1422 202 1607 1658 34 27 
Grayson 2013 8030 457 1367 192 1447 1124 33 33 
Grayson 2014 8415 454 1378 167 1430 1426 19 52 
Grayson 2015 8344 405 1302 165 1419 1035 14 47 
Grayson 2016 8117 374 1367 132 1350 983 13 63 
Grayson 2017 7637 303 1372 118 1151 821 22 75 
Green 2012 2796 122 348 36 522 393 4 29 
Green 2013 2657 97 321 34 448 296 9 22 
Green 2014 2702 91 332 37 420 317 9 39 
Green 2015 2598 93 337 38 429 265 2 58 
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County Year OAP HDOAP LTOAP LTHDOAP CPOAB CPOA LAOAP BPN 
Green 2016 2574 78 362 35 385 246 3 62 
Green 2017 2290 66 336 30 304 178 0 72 
Greenup 2012 8043 584 1125 200 1441 1189 44 165 
Greenup 2013 7990 529 1125 187 1294 1197 27 218 
Greenup 2014 7708 454 950 167 1132 886 34 273 
Greenup 2015 7329 357 739 98 876 694 29 300 
Greenup 2016 7070 272 709 78 773 586 27 337 
Greenup 2017 6486 222 697 66 748 515 27 373 
Hancock 2012 1508 85 134 20 202 150 15 9 
Hancock 2013 1434 76 139 20 186 146 14 10 
Hancock 2014 1490 62 151 16 178 156 8 6 
Hancock 2015 1508 74 165 19 182 137 19 13 
Hancock 2016 1590 64 177 14 160 132 11 14 
Hancock 2017 1514 50 146 8 148 93 7 12 
Hardin 2012 23571 1375 2313 513 2713 2807 123 97 
Hardin 2013 22530 1179 2270 472 2416 2289 133 106 
Hardin 2014 23388 1308 2464 455 2384 3167 93 132 
Hardin 2015 23545 1116 2326 397 2245 2171 71 154 
Hardin 2016 24040 1005 2552 332 2257 2040 79 241 
Hardin 2017 23235 852 2702 299 2022 1773 51 448 
Harlan 2012 9441 586 2325 242 1895 2114 26 676 
Harlan 2013 8449 453 1996 174 1613 1271 32 760 
Harlan 2014 8588 395 1852 183 1445 1125 34 723 
Harlan 2015 8467 357 1819 159 1364 990 30 531 
Harlan 2016 8124 317 1694 145 1212 867 21 512 
Harlan 2017 7416 286 1650 143 1040 772 11 567 
Harrison 2012 4991 383 546 124 766 767 34 74 
Harrison 2013 4455 237 488 87 616 442 38 122 
Harrison 2014 4769 225 518 84 737 527 33 144 
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Harrison 2015 4882 232 606 81 726 521 19 182 
Harrison 2016 4602 197 553 83 569 392 16 196 
Harrison 2017 4157 166 494 54 472 337 7 274 
Hart 2012 4223 240 507 93 562 625 14 26 
Hart 2013 3994 209 507 79 506 464 26 30 
Hart 2014 4111 230 541 90 495 538 12 41 
Hart 2015 4088 201 526 77 456 399 7 65 
Hart 2016 4008 182 573 68 412 385 7 68 
Hart 2017 3710 154 577 59 400 300 1 73 
Henderson 2012 13047 775 1871 230 2177 1836 66 14 
Henderson 2013 12455 772 1755 250 2056 1648 49 23 
Henderson 2014 12597 871 1818 258 2136 1949 55 34 
Henderson 2015 12470 793 1895 270 2212 1455 52 35 
Henderson 2016 12438 698 1928 251 2201 1323 51 53 
Henderson 2017 11390 590 1874 220 1940 1141 31 95 
Henry 2012 5329 268 532 95 712 620 24 28 
Henry 2013 4800 245 568 90 574 519 16 43 
Henry 2014 4995 263 616 87 591 652 20 67 
Henry 2015 5000 268 638 91 602 512 11 78 
Henry 2016 4998 225 625 61 561 459 11 74 
Henry 2017 4594 190 612 67 478 372 9 91 
Hickman 2012 956 26 123 3 152 96 9 6 
Hickman 2013 898 22 110 5 128 75 4 7 
Hickman 2014 894 38 110 9 131 113 4 7 
Hickman 2015 937 46 135 11 149 91 2 5 
Hickman 2016 868 40 123 8 118 81 1 10 
Hickman 2017 797 33 128 5 115 86 3 10 
Hopkins 2012 13662 897 2356 274 2490 2240 50 119 
Hopkins 2013 12420 845 2224 260 2239 2171 41 143 
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Hopkins 2014 12534 863 2151 261 2081 2101 41 140 
Hopkins 2015 12415 677 2079 238 1956 1341 28 182 
Hopkins 2016 12023 587 2072 211 1854 1240 26 219 
Hopkins 2017 11334 518 1926 173 1564 1108 21 246 
Jackson 2012 4048 292 720 114 683 755 14 102 
Jackson 2013 3662 222 696 90 534 541 14 124 
Jackson 2014 3688 199 662 73 485 528 24 169 
Jackson 2015 3605 181 678 67 429 416 14 199 
Jackson 2016 3422 161 619 64 383 390 6 221 
Jackson 2017 3244 135 607 53 341 316 7 256 
Jefferson 2012 189393 10504 19921 3550 23209 20468 579 1316 
Jefferson 2013 174827 8659 18652 3058 20149 16088 733 1411 
Jefferson 2014 174776 9749 18934 2872 18874 24281 474 1938 
Jefferson 2015 174691 8127 18293 2617 18197 13795 402 2404 
Jefferson 2016 169565 7386 18124 2450 16925 12420 349 2626 
Jefferson 2017 156683 6451 17644 2181 14944 10545 383 2956 
Jessamine 2012 11544 842 1616 362 1450 1589 130 246 
Jessamine 2013 10902 735 1484 327 1217 1345 92 323 
Jessamine 2014 11617 726 1426 294 1173 1486 112 463 
Jessamine 2015 12004 668 1453 270 1195 1253 84 554 
Jessamine 2016 11774 579 1354 227 1059 1122 87 554 
Jessamine 2017 10863 487 1284 186 915 968 80 666 
Johnson 2012 8278 535 1690 209 2684 1611 21 241 
Johnson 2013 7501 369 1248 114 2032 1033 14 359 
Johnson 2014 7324 283 1200 112 1673 909 19 423 
Johnson 2015 6995 345 1209 171 1591 847 28 434 
Johnson 2016 7009 305 1133 165 1467 764 19 521 
Johnson 2017 6726 269 1137 133 1353 694 19 641 
Kenton 2012 36758 2779 4617 1234 5357 4119 171 461 
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Kenton 2013 34513 2256 3951 1017 4289 3129 201 418 
Kenton 2014 34264 2156 3668 909 3780 3764 163 458 
Kenton 2015 33901 1757 3593 851 3601 2501 174 603 
Kenton 2016 32893 1623 3464 746 3286 2258 133 697 
Kenton 2017 30087 1393 3336 645 2852 2022 116 850 
Knott 2012 4424 355 1256 137 1165 1044 12 125 
Knott 2013 4131 208 1184 83 919 649 11 141 
Knott 2014 4329 209 1200 105 892 601 14 210 
Knott 2015 4185 207 1153 90 846 530 11 272 
Knott 2016 3929 183 1102 80 777 454 11 343 
Knott 2017 3685 134 1064 63 673 369 6 401 
Knox 2012 8656 507 2269 181 2300 1869 25 307 
Knox 2013 8053 413 2104 155 2074 1342 35 421 
Knox 2014 8311 390 2027 169 2067 1563 38 548 
Knox 2015 8183 349 1725 158 1751 1060 33 567 
Knox 2016 7664 341 1656 155 1560 1012 26 511 
Knox 2017 7118 274 1617 122 1411 846 21 427 
Larue 2012 3604 224 407 94 573 639 15 12 
Larue 2013 3531 187 429 80 558 421 13 13 
Larue 2014 3592 223 463 88 558 511 11 19 
Larue 2015 3547 210 422 69 576 412 5 36 
Larue 2016 3538 184 476 67 531 354 11 30 
Larue 2017 3261 149 500 65 485 329 4 33 
Laurel 2012 15365 1046 3106 358 3214 3683 50 478 
Laurel 2013 14233 714 2744 294 2683 2188 79 629 
Laurel 2014 14605 647 2588 250 2554 2131 81 781 
Laurel 2015 14377 638 2472 265 2386 1761 59 902 
Laurel 2016 13718 629 2391 251 2121 1632 53 998 
Laurel 2017 12597 491 2133 223 1811 1295 34 1078 
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Lawrence 2012 4842 317 903 110 1189 963 17 198 
Lawrence 2013 4315 211 743 61 940 593 15 202 
Lawrence 2014 4341 173 654 64 759 476 13 293 
Lawrence 2015 4276 183 576 59 719 434 16 345 
Lawrence 2016 4242 155 585 66 705 386 7 377 
Lawrence 2017 3993 138 503 43 582 338 8 430 
Lee 2012 2478 138 581 65 698 425 14 98 
Lee 2013 2210 126 522 55 631 435 11 124 
Lee 2014 2357 133 564 51 585 453 16 190 
Lee 2015 2284 104 510 48 544 275 6 207 
Lee 2016 2296 122 454 40 527 303 5 230 
Lee 2017 1967 95 409 36 444 247 3 269 
Leslie 2012 3923 410 1198 187 993 1045 17 133 
Leslie 2013 3730 281 1142 119 956 828 15 204 
Leslie 2014 3920 242 1111 112 994 632 21 261 
Leslie 2015 3714 187 926 87 906 449 8 293 
Leslie 2016 3437 151 946 66 840 398 8 330 
Leslie 2017 3120 108 807 55 458 311 4 409 
Letcher 2012 7617 486 1942 156 1596 1732 29 467 
Letcher 2013 6747 302 1644 116 1184 1166 24 526 
Letcher 2014 6919 243 1588 103 1066 857 18 577 
Letcher 2015 6936 221 1461 91 933 646 13 541 
Letcher 2016 6618 202 1367 68 868 668 24 555 
Letcher 2017 6037 166 1322 61 608 503 8 656 
Lewis 2012 2981 179 339 55 423 393 19 46 
Lewis 2013 2745 126 335 46 367 317 18 84 
Lewis 2014 2925 121 297 44 334 277 13 135 
Lewis 2015 2951 115 283 37 337 277 9 114 
Lewis 2016 2796 104 328 32 360 281 17 116 
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Lewis 2017 2606 89 297 23 340 238 11 117 
Lincoln 2012 6802 516 1279 232 1402 1087 33 128 
Lincoln 2013 6349 395 1292 169 1315 911 42 159 
Lincoln 2014 6392 426 1214 153 1299 1090 43 194 
Lincoln 2015 6508 352 1231 146 1194 775 23 245 
Lincoln 2016 6197 319 1150 118 1085 692 26 251 
Lincoln 2017 5882 253 1092 81 877 547 18 271 
Livingston 2012 3245 210 655 64 720 551 12 11 
Livingston 2013 3054 194 559 59 646 410 9 20 
Livingston 2014 2952 237 577 65 587 572 10 22 
Livingston 2015 3081 202 577 68 588 401 9 23 
Livingston 2016 3056 176 577 57 620 377 10 28 
Livingston 2017 2870 181 552 51 530 341 10 52 
Logan 2012 7060 348 733 113 847 721 36 35 
Logan 2013 6661 337 763 129 742 708 28 45 
Logan 2014 6580 371 778 144 671 782 29 56 
Logan 2015 6692 368 813 141 629 630 30 67 
Logan 2016 6750 333 904 130 599 601 21 64 
Logan 2017 6547 287 897 116 521 537 20 84 
Lyon 2012 2123 119 337 31 459 304 10 13 
Lyon 2013 2000 107 292 27 382 228 4 15 
Lyon 2014 2039 120 307 33 398 272 9 15 
Lyon 2015 2030 132 314 34 369 262 9 17 
Lyon 2016 1949 107 302 25 363 223 8 21 
Lyon 2017 1832 98 282 26 342 192 13 30 
Madison 2012 19768 1603 2809 589 2603 3650 115 476 
Madison 2013 17827 1170 2571 478 2126 2334 115 644 
Madison 2014 18442 1161 2547 434 2029 2510 134 800 
Madison 2015 18913 985 2601 397 1947 2150 102 973 
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Madison 2016 18490 834 2444 333 1797 1988 93 1069 
Madison 2017 17283 721 2359 271 1591 1692 70 1363 
Magoffin 2012 4411 322 861 140 1293 1060 12 283 
Magoffin 2013 3942 194 715 82 1060 610 9 337 
Magoffin 2014 4104 175 727 81 895 512 16 381 
Magoffin 2015 4031 203 792 100 955 500 29 395 
Magoffin 2016 3921 172 798 92 935 493 15 508 
Magoffin 2017 3735 155 786 83 855 424 12 610 
Marion 2012 5088 261 638 102 757 664 7 80 
Marion 2013 4765 208 672 98 699 553 17 85 
Marion 2014 4969 236 653 96 690 659 9 121 
Marion 2015 4875 246 683 115 669 522 3 163 
Marion 2016 4748 222 703 115 592 471 11 171 
Marion 2017 4480 188 680 98 553 420 7 201 
Marshall 2012 8514 611 1234 182 1768 1203 99 70 
Marshall 2013 8164 543 1276 182 1564 989 37 78 
Marshall 2014 8166 577 1300 169 1543 1182 34 89 
Marshall 2015 8529 577 1336 162 1558 978 47 121 
Marshall 2016 8647 548 1385 164 1583 943 30 147 
Marshall 2017 7979 512 1373 156 1412 859 30 177 
Martin 2012 3893 246 788 105 1330 883 8 126 
Martin 2013 3579 178 571 66 900 459 33 202 
Martin 2014 3639 173 577 75 763 457 15 235 
Martin 2015 3513 154 533 68 745 376 32 272 
Martin 2016 3427 126 545 60 719 427 5 331 
Martin 2017 3201 107 557 57 652 329 6 428 
Mason 2012 3982 195 383 63 499 550 34 62 
Mason 2013 3704 154 376 46 458 392 41 78 
Mason 2014 3834 125 342 41 444 355 34 73 
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Mason 2015 3799 115 327 38 425 320 22 79 
Mason 2016 3778 100 291 30 433 289 12 61 
Mason 2017 3308 80 298 27 370 248 8 78 
McCracken 2012 18855 1292 2818 336 3527 2673 83 137 
McCracken 2013 17798 1039 2503 251 3075 1956 73 159 
McCracken 2014 17700 1045 2623 242 2967 2491 62 193 
McCracken 2015 18060 958 2799 255 2962 1935 63 242 
McCracken 2016 18251 938 2906 256 2991 1897 54 281 
McCracken 2017 16911 874 2920 224 2672 1697 77 323 
McCreary 2012 4600 336 971 117 1120 1032 33 124 
McCreary 2013 4177 261 874 83 1067 835 23 176 
McCreary 2014 4459 220 858 89 995 654 29 277 
McCreary 2015 4440 203 823 97 895 451 21 289 
McCreary 2016 4148 172 785 84 658 379 12 366 
McCreary 2017 3896 179 818 90 498 320 10 370 
McLean 2012 2725 137 352 38 367 340 11 8 
McLean 2013 2439 134 355 38 302 308 13 16 
McLean 2014 2523 133 341 40 321 280 19 22 
McLean 2015 2524 109 335 43 298 234 12 23 
McLean 2016 2499 116 368 42 301 222 4 24 
McLean 2017 2426 104 347 30 292 211 10 35 
Meade 2012 4916 275 612 102 539 634 12 27 
Meade 2013 4549 235 530 94 443 466 22 34 
Meade 2014 4804 243 563 87 469 550 16 48 
Meade 2015 4780 210 521 62 464 459 15 35 
Meade 2016 4716 191 542 68 408 428 15 43 
Meade 2017 4438 143 538 60 370 339 6 61 
Menifee 2012 1663 158 276 50 261 279 15 49 
Menifee 2013 1625 106 276 35 239 251 7 65 
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Table 5.1 Continued 
County Year OAP HDOAP LTOAP LTHDOAP CPOAB CPOA LAOAP BPN 
Menifee 2014 1722 98 283 39 217 254 14 88 
Menifee 2015 1749 93 299 28 231 218 13 111 
Menifee 2016 1661 76 277 32 217 183 2 128 
Menifee 2017 1522 56 263 20 190 174 6 146 
Mercer 2012 6059 446 917 201 955 884 45 111 
Mercer 2013 5589 351 796 147 861 712 42 131 
Mercer 2014 5745 321 782 138 819 718 41 179 
Mercer 2015 6034 302 794 113 796 644 39 204 
Mercer 2016 5637 257 755 97 711 621 22 197 
Mercer 2017 5112 227 711 88 563 488 18 236 
Metcalfe 2012 2986 106 349 42 435 367 7 17 
Metcalfe 2013 2863 110 365 45 438 332 8 37 
Metcalfe 2014 3012 117 403 33 457 342 4 33 
Metcalfe 2015 2993 114 426 32 452 332 11 43 
Metcalfe 2016 2941 93 439 36 428 262 9 62 
Metcalfe 2017 2830 83 434 31 375 229 3 76 
Monroe 2012 3521 211 464 73 792 490 12 10 
Monroe 2013 3237 219 436 89 772 469 12 16 
Monroe 2014 3241 202 451 83 685 428 9 18 
Monroe 2015 3117 160 479 71 538 307 7 29 
Monroe 2016 2977 150 485 60 497 267 11 87 
Monroe 2017 2872 126 498 53 408 242 7 89 
Montgomery 2012 6843 749 1109 294 1099 1251 79 197 
Montgomery 2013 6700 546 1080 229 906 974 26 270 
Montgomery 2014 7086 536 1047 198 886 983 51 369 
Montgomery 2015 7064 458 1082 195 872 903 32 509 
Montgomery 2016 6910 431 1032 183 812 846 18 593 
Montgomery 2017 6262 367 983 142 744 710 15 664 
Morgan 2012 3310 175 448 78 576 442 8 60 
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Table 5.1 Continued 
County Year OAP HDOAP LTOAP LTHDOAP CPOAB CPOA LAOAP BPN 
Morgan 2013 2959 146 395 64 479 364 9 108 
Morgan 2014 3179 126 425 59 434 366 16 144 
Morgan 2015 3012 127 397 55 425 310 4 176 
Morgan 2016 3040 131 404 53 392 317 8 191 
Morgan 2017 2879 84 394 37 367 279 3 206 
Muhlenberg 2012 9299 528 1867 182 1816 1551 28 98 
Muhlenberg 2013 8565 456 1654 163 1562 1089 27 155 
Muhlenberg 2014 8680 475 1665 179 1627 1130 43 207 
Muhlenberg 2015 8638 490 1663 184 1580 1003 29 240 
Muhlenberg 2016 8441 460 1717 173 1491 920 34 300 
Muhlenberg 2017 8038 390 1650 136 1347 840 29 311 
Nelson 2012 12843 657 1388 223 1787 1462 29 103 
Nelson 2013 12389 575 1372 213 1630 1212 43 110 
Nelson 2014 12468 589 1259 199 1468 1444 25 136 
Nelson 2015 12296 518 1288 197 1401 1044 43 178 
Nelson 2016 12150 494 1302 178 1232 1031 24 181 
Nelson 2017 11040 435 1384 155 1142 884 27 218 
Nicholas 2012 2107 208 299 77 325 380 18 47 
Nicholas 2013 1853 134 279 57 258 256 9 81 
Nicholas 2014 1812 121 252 56 236 244 14 93 
Nicholas 2015 1887 108 304 56 260 230 10 124 
Nicholas 2016 1868 100 272 53 217 174 10 159 
Nicholas 2017 1717 85 254 36 159 161 4 174 
Ohio 2012 7184 464 1155 152 1313 1064 20 16 
Ohio 2013 6564 395 1151 138 1141 786 32 37 
Ohio 2014 6586 383 1115 133 1153 836 20 48 
Ohio 2015 6756 331 1171 122 1108 686 7 42 
Ohio 2016 6516 270 1187 93 953 559 15 68 
Ohio 2017 6290 247 1132 84 816 496 23 97 
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Table 5.1 Continued 
County Year OAP HDOAP LTOAP LTHDOAP CPOAB CPOA LAOAP BPN 
Oldham 2012 11364 547 847 170 1077 1027 32 93 
Oldham 2013 10964 469 889 171 1018 852 36 99 
Oldham 2014 10610 513 897 150 1027 1169 23 98 
Oldham 2015 10574 435 893 127 1001 767 33 145 
Oldham 2016 10540 409 880 106 935 718 27 153 
Oldham 2017 9771 359 852 97 822 625 23 158 
Owen 2012 2093 128 301 49 343 263 8 23 
Owen 2013 1966 107 290 46 286 237 9 32 
Owen 2014 1907 107 286 44 235 247 14 40 
Owen 2015 1975 101 307 47 246 201 3 51 
Owen 2016 1934 87 272 35 202 167 6 55 
Owen 2017 1805 82 278 33 179 154 6 73 
Owsley 2012 1982 138 523 57 579 440 8 88 
Owsley 2013 1812 113 475 49 526 372 14 128 
Owsley 2014 1908 119 522 44 449 606 6 159 
Owsley 2015 1821 86 508 33 426 282 3 187 
Owsley 2016 1711 73 471 31 369 219 1 208 
Owsley 2017 1579 64 437 26 298 211 3 237 
Pendleton 2012 3642 277 492 117 568 436 21 62 
Pendleton 2013 3437 232 478 106 460 363 14 62 
Pendleton 2014 3469 212 439 85 414 339 10 54 
Pendleton 2015 3431 194 438 81 394 278 16 79 
Pendleton 2016 3402 198 453 87 371 298 11 111 
Pendleton 2017 3212 167 447 83 337 267 7 111 
Perry 2012 10043 1061 2850 536 2340 2141 28 330 
Perry 2013 9366 737 2619 366 2113 1545 43 431 
Perry 2014 9957 600 2479 292 1993 1321 40 668 
Perry 2015 9573 508 2426 246 1830 1063 23 807 
Perry 2016 8953 466 2363 252 1693 950 19 964 
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Table 5.1 Continued 
County Year OAP HDOAP LTOAP LTHDOAP CPOAB CPOA LAOAP BPN 
Perry 2017 8263 401 2273 197 1399 843 22 1157 
Pike 2012 20280 1145 4911 363 5873 4416 73 1077 
Pike 2013 18505 796 4306 248 4495 3260 54 1292 
Pike 2014 18259 747 4197 240 3986 3099 46 1535 
Pike 2015 17836 627 3712 227 3544 2387 54 1593 
Pike 2016 17574 562 3566 213 3336 2142 41 1744 
Pike 2017 16572 501 3493 203 2841 1904 26 2143 
Powell 2012 4238 549 868 195 951 937 31 115 
Powell 2013 3749 342 810 148 770 643 18 170 
Powell 2014 3969 336 771 141 747 644 26 294 
Powell 2015 3960 278 777 111 689 545 12 351 
Powell 2016 3889 248 767 103 681 517 8 365 
Powell 2017 3620 227 741 97 582 459 11 438 
Pulaski 2012 16851 1110 2952 403 3628 2752 75 440 
Pulaski 2013 15487 885 2657 327 3354 2118 101 506 
Pulaski 2014 16132 830 2676 310 3313 2260 123 698 
Pulaski 2015 16022 785 2586 315 3075 1866 92 745 
Pulaski 2016 15451 683 2332 280 2668 1609 88 745 
Pulaski 2017 14344 586 2190 230 2068 1393 51 791 
Robertson 2012 486 37 49 10 88 78 3 6 
Robertson 2013 408 23 52 9 71 46 3 11 
Robertson 2014 476 24 63 11 69 57 4 11 
Robertson 2015 493 27 69 8 82 49 0 10 
Robertson 2016 460 18 65 5 59 41 1 4 
Robertson 2017 413 16 57 5 55 29 0 20 
Rockcastle 2012 4854 470 995 155 1173 963 34 96 
Rockcastle 2013 4180 327 805 112 933 613 35 146 
Rockcastle 2014 4382 310 800 115 862 614 31 223 
Rockcastle 2015 4347 306 864 126 828 577 27 239 
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Table 5.1 Continued 
County Year OAP HDOAP LTOAP LTHDOAP CPOAB CPOA LAOAP BPN 
Rockcastle 2016 4229 258 798 103 758 535 19 230 
Rockcastle 2017 4034 211 762 75 623 440 16 264 
Rowan 2012 5197 352 660 134 795 748 31 146 
Rowan 2013 4891 287 608 101 740 583 27 161 
Rowan 2014 5310 238 613 93 706 585 31 213 
Rowan 2015 5288 214 647 88 641 508 16 244 
Rowan 2016 4957 209 620 80 591 496 21 295 
Rowan 2017 4439 175 529 63 443 410 8 337 
Russell 2012 5176 266 803 97 1185 890 31 182 
Russell 2013 4804 219 863 83 1173 657 32 174 
Russell 2014 4924 182 833 75 1113 604 16 254 
Russell 2015 5136 171 851 74 1084 528 17 299 
Russell 2016 4844 168 802 68 934 463 14 316 
Russell 2017 4380 116 715 45 688 353 8 365 
Scott 2012 12073 656 1201 228 1291 1407 61 242 
Scott 2013 11317 506 1131 183 1127 1191 56 390 
Scott 2014 11791 497 1128 164 1121 1300 61 439 
Scott 2015 12266 468 1232 153 1070 1154 51 504 
Scott 2016 12057 433 1186 135 1012 1055 46 544 
Scott 2017 11179 382 1093 114 858 956 42 637 
Shelby 2012 9797 549 872 175 1061 1176 30 67 
Shelby 2013 9219 433 846 153 926 775 39 88 
Shelby 2014 9371 452 875 135 892 1042 42 96 
Shelby 2015 9411 427 877 133 911 717 25 127 
Shelby 2016 9368 413 921 124 858 723 35 134 
Shelby 2017 8543 336 895 103 721 610 29 150 
Simpson 2012 4811 293 591 99 790 582 13 32 
Simpson 2013 4326 237 496 77 605 352 23 31 
Simpson 2014 4533 210 539 78 562 437 24 38 
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Table 5.1 Continued 
County Year OAP HDOAP LTOAP LTHDOAP CPOAB CPOA LAOAP BPN 
Simpson 2015 4417 210 556 81 497 355 24 56 
Simpson 2016 4279 186 540 71 446 348 16 58 
Simpson 2017 3849 159 474 52 360 275 13 63 
Spencer 2012 4627 343 553 117 673 614 14 33 
Spencer 2013 4167 287 502 105 577 470 20 35 
Spencer 2014 4243 271 508 93 496 533 16 46 
Spencer 2015 4284 257 511 84 499 416 9 64 
Spencer 2016 4085 241 531 89 473 356 12 84 
Spencer 2017 3871 197 511 67 375 300 9 94 
Taylor 2012 6892 343 846 143 1349 835 17 119 
Taylor 2013 6707 297 873 138 1196 765 20 115 
Taylor 2014 6946 303 900 134 1203 783 13 182 
Taylor 2015 6753 309 877 131 1132 697 15 271 
Taylor 2016 6534 265 824 111 991 619 17 270 
Taylor 2017 6006 230 815 100 807 523 12 278 
Todd 2012 2402 122 314 39 320 253 10 5 
Todd 2013 2200 94 341 38 310 224 12 9 
Todd 2014 2367 115 400 45 305 268 10 11 
Todd 2015 2385 112 345 38 269 219 9 12 
Todd 2016 2367 115 352 44 263 238 10 14 
Todd 2017 2324 109 393 41 264 249 14 22 
Trigg 2012 3681 208 420 60 622 493 7 21 
Trigg 2013 3527 175 383 48 557 408 15 34 
Trigg 2014 3556 179 402 49 515 514 15 31 
Trigg 2015 3498 174 403 60 466 369 15 25 
Trigg 2016 3379 167 442 64 466 372 14 30 
Trigg 2017 3300 181 451 56 403 336 12 42 
Trimble 2012 1973 161 245 55 290 325 15 16 
Trimble 2013 1827 153 277 53 279 360 14 26 
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County Year OAP HDOAP LTOAP LTHDOAP CPOAB CPOA LAOAP BPN 
Trimble 2014 1905 145 289 45 276 301 14 33 
Trimble 2015 1911 106 283 36 274 192 4 42 
Trimble 2016 1739 106 294 31 229 207 7 52 
Trimble 2017 1579 71 242 25 192 152 3 48 
Union 2012 4559 275 741 94 925 689 16 14 
Union 2013 4189 284 674 91 788 729 21 11 
Union 2014 4200 257 704 83 802 596 7 15 
Union 2015 4244 243 719 75 809 498 15 23 
Union 2016 4137 222 646 68 732 451 10 16 
Union 2017 3737 170 627 57 598 355 8 13 
Warren 2012 28604 1398 2863 502 3499 3204 106 188 
Warren 2013 26772 1196 2827 476 2993 2527 73 206 
Warren 2014 27197 1248 2845 442 2863 3078 72 230 
Warren 2015 27946 1164 2897 427 2713 2324 71 280 
Warren 2016 26802 1029 2992 411 2418 2117 59 272 
Warren 2017 25628 942 3022 359 1949 1867 45 348 
Washington 2012 2781 132 278 47 364 320 19 28 
Washington 2013 2521 116 272 48 303 237 9 49 
Washington 2014 2578 116 253 48 287 229 7 65 
Washington 2015 2703 116 222 45 276 231 8 78 
Washington 2016 2571 122 254 44 283 241 8 67 
Washington 2017 2434 91 245 32 256 211 4 77 
Wayne 2012 5639 247 885 76 1125 799 46 100 
Wayne 2013 5676 247 872 75 1073 696 18 139 
Wayne 2014 5858 195 934 65 1117 694 26 211 
Wayne 2015 5646 228 957 87 1003 594 10 230 
Wayne 2016 5327 201 872 78 875 573 15 231 
Wayne 2017 4926 166 796 58 730 437 11 259 
Webster 2012 4089 288 686 85 748 665 11 25 
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County Year OAP HDOAP LTOAP LTHDOAP CPOAB CPOA LAOAP BPN 
Webster 2013 3768 230 630 70 661 533 14 22 
Webster 2014 3903 327 637 93 658 934 16 32 
Webster 2015 3833 222 690 70 655 448 17 29 
Webster 2016 3731 202 711 67 662 423 7 46 
Webster 2017 3528 164 658 60 577 356 4 46 
Whitley 2012 15797 1059 3166 433 4127 2958 88 485 
Whitley 2013 14626 906 2976 382 3427 2446 76 702 
Whitley 2014 15007 773 2790 332 3198 2297 102 956 
Whitley 2015 14850 741 2541 333 2924 1914 59 894 
Whitley 2016 13885 633 2445 276 2573 1796 61 866 
Whitley 2017 12987 578 2399 258 2145 1588 46 974 
Wolfe 2012 2943 221 739 89 911 596 7 65 
Wolfe 2013 2771 184 757 75 818 532 8 79 
Wolfe 2014 2823 172 787 70 781 637 10 101 
Wolfe 2015 2665 147 741 64 725 407 8 118 
Wolfe 2016 2533 121 644 62 596 310 7 124 
Wolfe 2017 2319 102 556 54 424 252 2 184 
Woodford 2012 5830 297 609 106 578 688 49 94 
Woodford 2013 5467 287 613 104 500 598 39 120 
Woodford 2014 5656 254 582 89 498 577 39 115 
Woodford 2015 5988 256 587 79 512 555 57 150 
Woodford 2016 5882 260 598 78 516 537 55 162 
Woodford 2017 5411 215 532 64 445 473 35 183 
Data Source: the Kentucky All Schedule Prescription Electronic Reporting (KASPER) program, Office of Inspector General 
(OIG), Cabinet for Health and Family Services, 2012 - 2017 
OAP (Opioid analgesic prescribing) = the number of residents with at least one opioid analgesic prescription; 
HDOAP (High-dose opioid analgesic prescribing) = the number of residents with at least seven consecutive days with daily 
cumulative dose of 100 morphine milligram equivalents or more;  
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LTOAP (Long-term opioid analgesic prescribing) = the number of residents with opioid analgesic prescriptions for at least 90 
consecutive days’ supply; 
LTHDOAP (Long-term high-dose opioid analgesic prescribing) = the number of residents with opioid analgesic prescriptions 
for at least 90 consecutive days’ supply at an average daily cumulative morphine milligram equivalent dose of 100 or greater; 
CPOAB (Concomitant prescribing of opioid analgesics and benzodiazepines) = the number of residents with simultaneous 
prescriptions for both an opioid analgesic and a benzodiazepine for at least seven consecutive days’ supply;  
CPOA (Concomitant prescribing of opioid analgesics) = the number of residents with at least seven consecutive days of two or 
more overlapping opioid analgesic prescriptions;  
LAOAP (Long-acting/ extended release opioid analgesic prescribing) = the number of opioid-naïve residents dispensed with 
long-acting/ extended release opioid prescription (an opioid-naïve resident is defined a person who had no prior opioid 
analgesic prescription for at least 180 days); 
BPN (Buprenorphine/naloxone prescribing) = the number of residents with at least one buprenorphine/ naloxone prescription. 
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